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The activation of B cells is the crucial step of the humoral immune response. This process is controlled
by the B cell receptor (BCR) signaling pathway which is initiated by antigen recognition. An elaborated
and detailed understanding of this pathway is of great interest given that its misregulation is involved in
the genesis of leukemia and immunodeficiencies. The adaptor protein SLP65 is a key regulator in BCR
signaling. After phosphorylation of its tyrosine residues, SLP65 serves as assembly site for enzymes and
facilitates their mutual activation. The activation of SLP65 by phosphorylation is a multi-step process
that requires SH3 domain-binding proline motifs within SLP65. These motifs mediate the interaction
of SLP65 with the adaptor protein CIN85. While it was known at the beginning of my doctoral thesis
project that the SLP65-CIN85 interaction supports the function of SLP65 in the BCR pathway, the un-
derlying mechanism remained totally unclear. The elucidation of this mechanism constitutes the aim of
my doctoral thesis.
By a genetic approach including chimeric proteins I could localize the effector function of CIN85 in
its C-terminal coiled-coil (CC) domain. To get insight into the function of the CIN85-CC, I determined
the protein interactome of CIN85 by SILAC-based mass spectrometry and investigated membrane lipid
binding by biochemical means. Next, I focused on the structure of the CIN85-CC in cooperation with
Prof. C. Griesinger’s group. By NMR-spectroscopy, we obtained the result that the CIN85-CC forms
a stable trimer. In further genetic experiments, I determined that oligomerization of SLP65 is essential
for its function in the BCR signaling pathway. Because CIN85 forms a trimer with nine SLP65 binding
sites, it provides the required oligomerization by simultaneous binding of several SLP65 molecules . Fur-
thermore, I found out that the SLP65 N-terminus is a pre-requisite for efficient SLP65 oligomerization.
As the N-terminus targets SLP65 to intracellular membranes, I could identify vesicles as the platform for
SLP65-oligomerization by CIN85. Because CIN85 and its homolog CD2AP interact with several other
proteins in the same manner as with SLP65, this mechanism is likely a general biological principle of




2.1 Discovery of antibodies and B cells: a story of 130 years
The immune system is the crucial line of defense of every multicellular organism against pathogens and
cancer development. Antibodies are soluble proteins that recognize and fight pathogens specifically. They
play a key role for an effective immune response. The importance of molecules with antibody-like function
can be seen from the fact that they are found in all vertebrates from lamprey on (reviewed in [28]).
The discovery of antibodies is closely linked to the discovery of the immune system itself. The first
scientific approach to understand the immunizing factors of our body were made in the ending 18th
century. Edward Jenner discovered that a human being was protected from smallpox infection after the
application of the relatively harmless cowpox virus (vaccinia) (reviewed in [193]). This was the birth of
the procedure nowadays known as vaccination.
The key discoveries for the evolvement of immunology as a science were made in the second half of
the 19th and the beginning of the 20th century (reviewed in [22] and [156]). They are linked to names
like Louis Pasteur (first rabies vaccination), Emil von Behring, Paul Ehrlich and Ilja Metchnikow. Two
fundamental concepts were developed in this time: There was the finding of Behring and Kitasato that
diphtheria-infected children could be cured by the application of the serum of diphtheria-infected rabbits
(serotherapy). The phenomenon was called humoral immunity, pathogen resistance transferred by liquid
(humor in Latin). This concept was postulated, amongst others, by P. Ehrlich, who proposed the ”side
chain theory”. Receptors (”side chains”) on the cell surface would recognize a pathogenic structure which
would lead to the secretion of soluble components that have the ability to neutralize pathogens. The
other concept, strongly promoted by I. Metchnikow and others, based on phagocytosis (Ancient Greek
for ”devouring by a cell”). It was observed that specific cells can internalize, phagocytose, pathogens like
bacteria. The process of phagocytosis was termed cellular immunity because it was conferred by cells,
not by serum. The two concepts of humoral and cellular immunity were initially seen contradictory. The
insight that both of them can be unified developed only later on.
The components of the humoral immune response, i.e. the serum molecules that could transfer immunity
between individuals, remained enigmatic for a long time. The molecules we know today as ”antibodies”,
a term used by P. Ehrlich already in 1891, were also called ”fixatives” or ”sensitizing substances” (I.
Metchnikow) at the beginning. Their astonishing abilities to cause blood agglutination, bacterial lysis,
and systemic protection of the organism at the same time led to confusion about their nature and ori-
gin. Until the 1940s, it was widely believed that phagocytotic cells were also responsible for antibody
production. This picture was challenged when M. Bjørneboe and H. Gormsen described the production
of antibodies by plasma cells and proposed that lymphocytes and plasma cells could be involved in the
generation of antibodies. The antibody production by plasma cells was later confirmed by experiments
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by A. Fagraeus and others. On the other hand, antibody production by lymphocytes was shown by N.
Jerne and A. Nordin. The question of the origin of plasma cells was still open until the 1960s, when it
could be shown by J. Gowans that plasma cells originate from lymphocytes which led to a conclusive
theory of the cellular source of antibodies.
Lymphocytes, already discovered in the late 19th century by A. Maximow, P. Ehrlich and others, could
not be assigned to an exact immunological function for a long time period. J. Murphy succeeded in
showing their importance for the immune response already in the 1910s, but their mechanistic role re-
mained completely unknown. In 1965, M. Cooper could classify lymphocytes according to the origin
of their development in T-lymphocytes (development in the Thymus) and B-lymphocytes (development
in the Bursa fabricii in chicken, in the bone marrow in mammals) (reviewed in [27]). His work could
also identify B-lymphocytes to be responsible for antibody production. T-lymphocytes have been shown
to play an essential role for cellular immunity and possess a supportive role in B-lymphocyte-mediated
production of antibodies.
Having established the cellular framework of antibody production, it was possible to investigate the
molecular mechanisms in detail. This was especially facilitated by the development of new biochemical
and genetic methods, most notably protein sequencing and polymerase chain reaction. One burning
question that had occurred in this time was how the immense repertoire of diverse antibodies against
virtually every pathogenic structure was generated. Germ-line coding of a myriad of different antibodies
would overextend the limits of the human genome. The model of DNA recombination was developed in
the 1970s by S. Tonegawa and others to explain this phenomenon (see section 2.2.1 for details).
The new methods enabled the identification of proteins and genes that are necessary for B cell function.
The recognition tool of B cells for their specific pathogen-derived target structure, the antigen, was iden-
tified to be a membrane-associated antibody, termed B cell receptor (BCR). This sensing of the antigen
presence is essential for the activation of a B cell and hence the whole humoral immune response. The
details of molecular processes involved in BCR-signal propagation have been studied since at least three
decades, yet there remain riddles and open questions that are still waiting to be solved.
2.2 Current understanding of BCR structure and signaling
2.2.1 Structure of antibodies and BCR
The BCR consist of an antibody molecule containing a transmembrane domain and the two associated
signaling chains Igα (CD79a) and Igβ (CD79b) [21, 146]. The Igα-Igβ heterodimer associates with the
membrane-anchored antibody by non-covalent interactions [21, 187, 139]. In general, the BCR allows the
B cell to detect the presence of its antigen by antigen binding of the antibody part and subsequent trans-
duction of this signal by the signaling chains. The molecular structure of an antibody, or immunoglobulin
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(Ig), molecule was elucidated in the 1960, mainly by works of R. Porter and G. Edelman (reviewed in
[188] and [162]). An immunoglobulin molecule consists of two Ig heavy chains and two Ig light chains.
They form a Y-shaped ensemble with individual chains interlinked by disulfide bridges. The two heavy
chains are linked by a varying number of disulfide bridges, while each light chain is linked to one heavy
chain by usually one disulfide bridge [101]. The antibody molecule can be separated in two functionally
distinct regions: the variable (V) domains which is responsible for antigen binding and the constant (C)
domains which exhibits the effector functions of the antibody. Each chain of the antibody consists of
several immunoglobulin super-family (IgSF) domains. IgSF domains display a characteristic fold of two
sandwiched β-sheets, linked by one disulfide bridge. The N-terminal IgSF domain of each Ig chain is the
V domain. The following C-terminal IgSF domains are C domains. Ig light chains contain only one C
domain, while Ig heavy chains contain three or four C domains, depending on the antibody class. The
first (CH1) and the second (CH2) domain surround a spacer region which forms a ”hinge”, resulting in
the Y-shaped structure of an antibody shown in Figure 2.1.
Fig. 2.1: Schematic structure of an antibody molecule. An antibody consists of two Ig light and to Ig
heavy chains. The chains are linked by disulfide bridges. The structure of an antibody resembles an ”Y”
due to the hinge region between the C domains CH1 and CH2. The antigen binding sites are located
within the V domains, the N-terminal IgSF domain of each chain. The following IgSG domains, the C
domains (three for IgG), provide binding sites for Fc receptors and complement components.
The entire repertoire of immunoglobulins has the ability to bind to a nearly all occuring antigenic pat-
terns, despite the structural heterogeneity of the antigens. This variety is enabled by genomic DNA-
recombination of the multigene family coding Ig heavy and light chains. The V domain is encoded by V,
D, and J gene segments, while the C domains are encoded by whole exons. The V, D, and J segments
are arranged by DNA-recombination to constitute a complete V domain. Because the genome contains
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multiple different versions of each segment, this enables a large combinatorial diversity of V domains.
Imprecise segment arrangement, the introduction of single point mutations, and the presence of two
different Ig light chains, termed κ and λ, can further enlarge the antibody repertoire. Altogether, the
number of potentially produced immunoglobulin molecules can be estimated to exceed 1016. The really
observed repertoire of antibodies and BCRs is nevertheless more limited. B cells undergo positive and
negative selection processes during their development (reviewed in [37]). Furthermore, the fate of a B cell
depends on the presence of its antigen. Generally, B cells that encounter their antigen start to proliferate.
Thereby they can out-compete other B cells, a process termed clonal selection by F. M. Burnet (reviewed
in [140]).
In contrast to the huge diversity of the V domains, the C domains of an antibody are germ-line encoded
without further modifications. The C domains of an Ig heavy chain can originate from nine different CH
genes, defining the human antibody classes. The CH region of each class can be linked to an arranged V
domain by DNA recombination in a process termed class switch recombination. The CH region undergoes
alternative splicing so that the same transcript can encode for a soluble antibody or a membrane bound
BCR.
2.2.2 Antibody function
In humans, there exist the five antibody classes IgA (subclasses IgA1 and IgA2), IgD, IgE, IgG (sub-
classes IgG1-IgG4) and IgM. They differ in their structure and as a result also in their biologic functions.
The effector functions of an antibody are determined by the C-terminal IgSF-domains of its Ig heavy
chain. The domains CH2-CH3 (for IgG, IgD and IgA) or CH2-CH4 (for IgM and IgE) represent the
Fc (Fragment crystallizable) part of an antibody. The Fc part mediates the antibody effector function
because it provides the ability to cause antibody-dependent cellular cytotoxicity (ADCC) or complement-
dependent cytotoxicity (CDC). ADCC is mediated by Fc receptors (FcRs) that bind to the Fc part of an
antibody. Many cells of the immune system, e.g. monocytes and macrophages, display Fc receptors on
their surface. This allows them to recognize antibody-coated structures like a pathogen cell and attack
them by phagocytosis or lysis due to cytotoxin secretion. By means of CDC, antibodies can target cells
for destruction by the complement system. The complement component C1q has the ability to bind to
Fc parts and to initiate the lysis of the antibody coated cell. Both processes, ADCC and CDC, depended
on the glycosylation pattern of the Fc part. Besides these effector functions, antibodies can also directly
neutralize their antigen. They can e.g. inhibit the cell entry of a pathogen by masking a protein structure
involved in this process or prevent the effect of toxins.
The membrane-bound form of IgM is the first BCR expressed in the B cell development and it is found
on all näıve B cells. Analogously, the secreted form of IgM is the first immunoglobulin produced in an
immune response. It forms a pentamer that has a high ability to work by CDC. As IgM antibodies
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originate normally from cells that did not experience extended affinity maturation in a germinal center
reaction, their affinity towards the antigen is low compared to other antibody classes. The pentameric
nature of IgM can compensate for this by an increased avidity.
The IgD-BCR is expressed on näıve B cells and originates from the same mRNA as the IgM-BCR by
alternative splicing. The serum levels of soluble IgD are extremely low. Its physiological function is not
yet clarified.
Monomeric IgG antibodies display the main portion of immunoglobulins in the serum. Because IgG
originates from class switching during a germinal center reaction, IgG antibodies have usually undergone
affinity maturation and possess a high affinity towards their antigen. This makes them efficient neutral-
izers for toxins and viruses. The Fc part of IgG binds to a variety of FcγRs present on many cell types of
the immune system, thus IgG mediates ADCC most efficiently. In comparison to the IgM- and IgD-BCR,
the IgG-BCR has an additional cytoplasmatic motif, the immunoreceptor tail tyrosine (ITT) motif that
contributes to BCR signaling in addition to Igα and Igβ [41].
IgA antibodies are the most abundant immunoglobulins at mucosal surfaces. They are mainly present
as monomers in the serum, but as dimers in the mucosa. IgA can act through neutralization of antigens,
preventing the uptake of pathogens at mucosal surfaces. It can also cause ADCC by binding to the FcαR
which is present e.g. on neutrophiles.
The level of soluble IgE antibodies is very low. They are implicated in the defense against parasites and
the triggering of allergies. IgE binds to the FcεR on mast cells with an extraordinary high affinity. Like
the IgG-BCR, the IgE-BCR possesses an ITT motif [41].
2.2.3 Activation of BCR signaling by antigen binding: still partially a mystery
Despite the structure of the BCR molecule is known in very detail, the oligomerization state of the BCR
in resting cells is still under debate (reviewed in [134]) . It has been found that the BCR is mainly
mobile and monomeric without stimulation by antigen binding [183]. Contradictory, it was reported
that the BCR is present on resting cells as a signaling inactive dimer or higher oligomer [198]. Also the
change of the oligomerization state after antigen binding is seen controversially. According to the most
established model, signaling-inactive BCR monomers are physically crosslinked by encountering their
antigen which leads in turn to the formation of oligomeric signaling-active BCR complexes, described
as microclusters (reviewed in [134]). On the other hand, the dissociation activation model proposes the
presence of signaling-inactive oligomers which would dissociate after antigen encounter, forming signaling
active monomers [198, 85].
Regardless which model of BCR activation might fit best to reality, the next essential step after the
antigen encounter is the phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs)
in the BCR-signaling chains Igα and Igβ. One ITAM consist of the sequence YXXI/LX7YXXI/L that
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is present once the Igα tail and once in the Igβ tail [145]. The kinases of the Src-family, mainly Lyn,
and the spleen tyrosine kinase (Syk) have been found to be implicated in ITAM phosphorylation [32, 85].
The exact triggering of the ITAM phosphorylation process remains partially unclear. Changes in BCR
conformation as well as a changed lipid environment of BCR oligomers seem to play a role (reviewed in
[134]). The tyrosine phosphorylation of the ITAMs creates binding sites for the tandem SH2 domains of
Syk [191, 45]. The interaction of Syk with the phosphorylated ITAMs leads to an enhancement of the Syk
kinase activity [150]. This activation of Syk is essential for BCR signaling because Syk phosphorylates
the adaptor protein SLP65, also called BLNK [47]. The complex of the two adaptor proteins SLP65 and
CIN85 is a key signaling transducing element for the BCR and the focus of this doctoral thesis.
2.3 SLP65: A central adaptor molecule for BCR signaling
Adaptor proteins is a term commonly used for proteins that possess no inherent enzymatic activity but
contain protein-protein or protein-lipid interaction domains. These can influence biological processes by
targeting ligands to specific subcellular localizations, regulate their enzymatic activities allosterically, or
enable the formation of protein complexes (reviewed in [95]). Adaptor proteins determine the spatial
and temporal organization of protein complexes in cells to a large extent (reviewed in [52]). Enzymes
and adaptor proteins cannot be strictly separated because many enzymes possess also adaptor protein
properties.
The adaptor SH2-domain containing leukocyte protein of 65 kDa (SLP65), also called B cell linker
(BLNK), B cell adaptor containing SH2 domain (BASH) or B cell activation (bca) gene product, was
identified as a protein heavily phosphorylated upon BCR stimulation [192, 47, 51, 49]. SLP65 is essential
for both, B cell development and activation [47, 195, 78, 110]. It is phosphorylated by Syk, but not by the
Tec-family kinase Btk [47]. For chicken SLP65, nine phosphorylated tyrosine residues can be detected,
seven of which are conserved in human SLP65 [122].
While the lack of SLP65 leads always to severe impairment of B cell development and function, the
degree of this impairment depends on the investigated species. In the chicken B cell line DT40, SLP65
deficiency abolishes completely Ca2+ mobilization upon BCR stimulation [75]. In contrast, there is still
Ca2+ mobilization detectable in SLP65-deficient mice, even if it is reduced compared to wildtype mice
[127, 78]. This remaining Ca2+ signaling is attributed to the complementation of SLP65 by other adaptors
expressed in mouse B cells, like SLP76 [170], or alternative pathways of Ca2+ mobilization, e.g. CD19
signaling ([38] and reviewed in [95]. As a result of an impaired B cell development, SLP65-deficient mice
show reduced B cell numbers [127]. The immune response to T-cell-independent antigens is abolished
[197]. Human patients with SLP65-deficiency show a severe immunodeficiency, they do not have mature
B cells and suffer from agammaglobulinemia [110].
SLP65 mediates Ca2+ influx by assembly of the Ca2+ initiation complex, consisting of Bruton’s ty-
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rosine kinase (Btk), phospholipase C-γ2 (PLC-γ2), and SLP65 itself [97].
Btk is a protein tyrosine kinase [142]. Mutations in the Btk gene lead to immunodeficiency in form of
X-linked agammaglobulinemia (XLA) [185, 123]. On cellular level, impaired Btk activation results in
reduction of BCR-induced Ca2+ signaling [141]. Btk has been shown to be activated by two mecha-
nisms upon BCR stimulation. Firstly, Btk is recruited to the plasma membrane by its binding to the
membrane lipid PIP3 which is produced after BCR stimulation [151]. Secondly, Btk is additionally ac-
tivated by tyrosine phosphorylation in its activation loop, carried out by Src-family kinases like Lyn
[143]. By its SH2 domain, Btk can bind to the phospho-tyrosine (pY) 96 of SLP65 [62, 171]. This
association is crucial for Btk function [172]. On one hand, it can promote Btk activity by bringing Btk
to the proximity of Lyn and Syk what might lead to phosphorylation of the Btk activation loop [7]. On
the other hand, the binding to SLP65 facilitates the interaction of Btk with its substrate PLC-γ2 [62, 97].
PLC-γ2 is activated by phosphorylation by Syk [175] and Btk [46]. This phosphorylation processes
are dependent on the presence of phosphorylated SLP65 that serves as a platform for the assembly of the
PLC-γ2-Btk complex (Ca2+ initiation complex) [75, 96]. The SH2 domains of PLC-γ2 bind to pY178 and
pY189 of SLP65 [47, 76]; its C2 domain binds to pY119 [39]. It has been shown that SLP65 assembles
Btk and PLC-γ2 in cis, as both proteins have to be bound to the same SLP65 molecule [24]. After full
activation, PLC-γ2 cleaves the plasma membrane lipid phosphatidylinositol-4,5-bisphosphate (PIP2) into
the second messenger molecules inositol trisphosphate (IP3) and diacyl-glycerol (DAG) [69]. IP3 binds
to the IP3 receptor in the membrane of the endoplasmic reticulum (ER), resulting in the release of Ca
2+
from the ER lumen to the cytosol by the opening of ion channels (reviewed in [11]). The emptying of
the ER Ca2+ reservoir leads in turn to the Stromal interaction molecule (STIM)-mediated opening of
store-operated Ca2+ channels (SOCs) in the plasma membrane. This results in the influx of extracellular
Ca2+ (reviewed in [105] and [155]).
The influx of Ca2+ and the generation of DAG initiate signaling cascades that lead in the end to the
activation of a variety of transcription factors. The elevated intracellular Ca2+ concentration is crucial for
the activation and nuclear translocation of the transcription factors NfκB and NFAT [4]. Furthermore,
high Ca2+ levels cooperate with DAG binding to activate the protein kinase C-β (PKC-β) ([120]. PKC-β
phosphorylates the protein CARD11, followed by the activation of the Inhibitor of κB kinase (IKK) and
the nuclear translocation of the transcription factor NfκB ([132], reviewed in [163]).
The DAG-mediated activation of PKC-β triggers as well signaling pathways leading to the activation of
the mitogen-activated protein kinases (MAPKs) JNK and p38 [56, 61]. DAG provides also a docking
site for RasGRP proteins [29]. This leads in turn to activation of the MAPK pathway via Ras, result-
ing in the activation of different transcription factors by the extracellular signal-regulated kinase (ERK)
[61]. ERK can alternatively be activated by an adaptor function of SLP65 independent of the Ca2+
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initiation complex. SLP65 binds the adaptor Grb2 which mediates the recruitment of the protein SOS.
SOS activates Ras and initiates MAPK activation [192, 47, 5]. The MAPKs activate many transcription
factors that play a role in lymphocyte activation, proliferation, and differentiation (reviewed in [148] and
[113]). Figure 2.2 gives an overview of the described signaling pathways initiated by BCR stimulation
and mediated by SLP65.
Depending on the developmental stage of the B cell and other extracellular signals, BCR signaling can
support activation and proliferation, but under certain circumstances also anergy or apoptosis (e.g. in
autoreactive B cells) (reviewed in [118]).
As an upstream event for all of the described pathways, the phosphorylation of SLP65 is a key step for
BCR signaling. While the signaling pathways downstream of SLP65 are quite well understood, there is
still one unsolved problem regarding this molecule itself. It is unclear how SLP65 is translocated from
the cytosol to the plasma membrane upon BCR stimulation. The adaptor protein homolog of SLP65 in T
cells, SLP76, has been shown to be targeted to the plasma membrane by binding to the membrane protein
LAT via the adaptor GADS [103]. However, for SLP65 no such membrane anchor could be identified yet.
The question of SLP65 membrane recruitment requires a closer look at the SLP65 domain structure and
its multiple interactions.
2.4 The SLP65 regions and their functions
SLP65 consists of a positively charged N-terminal region, a central proline rich region and a C-terminal
SH2 domain (Figure 2.3).
The N-terminal region of SLP65 has been described to form a leucine zipper which associates presumably
with a membrane protein to provide SLP65 membrane anchoring [87]. In contrast, our analyses pointed to
the direction that the N-terminus is not primarily a protein-protein-interaction-mediating leucine zipper
but a lipid interaction module. It anchors SLP65 to membranes, dependent on their curvature [40, 136].
The N-terminus is crucially required for the translocation of SLP65 to the plasma membrane. It has been
shown that the SLP65 N-terminus can be substituted by a lipid binding device, namely a myristoylation
signal [87] or the membrane anchoring domain of TIRAP [67, 18].
The C-terminal SH2 domain of SLP65 is essential for the anchoring of SLP65 to the plasma membrane
and the BCR [2]. It binds to the non-ITAM pY204 in the tail of Igα [42, 79]. However, in a chimeric
CD8-Igα/CD8-Igβ model, the SLP65-Igα interaction was partially dispensable, questioning its relevance
for SLP65 membrane and BCR recruitment under all conditions [135]. Consistent with this observation,
transgenic mice with a Y-to-F exchange of Y204 of Igα showed that the SLP65-Igα interaction is only
important for T-cell-independent immune responses [129]. The SH2 domain does also bind to the kinase
HPK1 [184, 154] and Syk. The Syk-SLP65 interaction can occur without Syk phosphorylation [2].
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Fig. 2.2: Overview of the SLP65 functions in BCR signaling. The BCR is activated by binding to its
antigen. This leads to phosphorylation of two tyrosines residues in the ITAM motif which display a
binding site for the SH2 domain of the kinase Syk. Activated Syk phosphorylates the adaptor protein
SLP65 which is in a steady complex with the adaptor CIN85. After its phosphorylation, SLP65 constitutes
a platform for the assembly of the kinase Btk and the lipase PLC-γ2, resulting in PLC-γ2 activation.
PLC-γ2 hydrolyzes the membrane lipid PIP2 to produce the second messengers DAG and IP3. IP3
mediates the influx of Ca2+ from the ER to the cytosol. DAG initiates the activation of the kinase
PKC-β, this process is enhanced by the elevated Ca2+ concentration. PKC-β activation and Ca2+ influx
trigger signaling cascades that lead in the end to the activation of the transcription factors NFAT, NfκB
and of the MAP kinases p38 and JNK. The activation of the MAP kinase Erk is triggered either by
SOS, a molecules recruited by SLP65 via Grb2, or alternatively by DAG via the recruitment of RasGRP
(not depicted). The activation of transcription factors and MAP kinases changes the transcriptional




Fig. 2.3: Schematic domain structure of SLP65. SLP65 possesses a positively charged N-terminal region
(aa 1-45, labeled by +). The following region of the protein is proline rich (aa 46-345, not labeled). This
region contains two PXXXPR motifs as binding sites for CIN85 (aa 242-247 and 307-312, depited by black
ovals). The C-terminus of the protein forms a SH2 domain (aa 346-453, SH2). The upper image displays
the known secondary structure elements in SLP65. Y represents a tyrosine residue that is phosphorylated
upon BCR stimulation. The pentagons represent proline residues of the two CIN85 binding sites.
The central proline rich region (PRR) of SLP65 contains the tyrosine residues that are phosphorylated
upon BCR stimulation and several proline-containing interaction motifs [121]. Three motifs with the
consensus sequence PXXXPR have been shown to interact with SH3 domains of the adaptor protein
CIN85 [122]. The second and third of these three motifs are responsible for the interaction of SLP65
with CIN85, while the first motif is dispensable [122]. The SLP65-CIN85 interaction is required for ef-
ficient SLP65 plasma membrane recruitment and phosphorylation and hence for the induction of Ca2+
mobilization [121]. So the SLP65-CIN85 interaction constitutes a third functionality that is important
for SLP65 plasma membrane recruitment, besides SLP65 N-terminus and SH2 domain.
2.5 CIN85: a multi-domain adaptor protein with still mysterious functions
The human Cbl-interacting protein of 85 kDa (CIN85) has been cloned and characterized by Take, Watan-
abe and colleagues. [176, 189]. Simultaneously, its homolog in rats was cloned by Gout and colleagues
and Bögler and colleagues who termed the protein Regulator of ubiquitous kinase (Ruk) respectively SH3
domain containing gene expressed in tumorigenic astrocytes (SETA) [55, 15]. From the beginning on,
CIN85 was characterized as an adaptor protein binding to the ubiquitin E3 ligase c-Cbl [176]. Together
with its homolog CD2AP, it forms a family of adaptor proteins [176, 55]. Its domain structure was
elucidated very soon after the cloning of the gene on the basis of bioinformatics [176, 189]. CIN85 has
three N-terminal SH3 domains followed by a proline-rich region (PRR) and a C-terminal coiled-coil (CC)
domain (Figure 2.4). The structure prediction could be confirmed by NMR spectroscopy studies. The
structure of all three SH3 domains is known ([1, 133]. Structure and oligomerization state of the CC were
solved in a collaboration of C. Griesinger’s and our group (see 4.10).
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Fig. 2.4: Schematic domain structure of CIN85. CIN85 possesses three N-terminal SH3 domains (aa 1-
328, SH3), followed by a proline-rich region (aa 329-599, PRR). The C-terminal part of CIN85 consists of
a coiled-coil domain (aa 600-665, CC). The upper image displays the known secondary structure elements
in CIN85.The pentagons represent proline residues of the intramolecular SH3 domain binding site within
the PRR.
CIN85 is an ubiquitously expressed protein that occurs in several isoforms [55]. The largest isoform
contains all the domains described above, while the other isoforms lack one, two, or all three SH3 do-
mains ([19, 44, 108]. The SH3 domains of CIN85 bind to atypical proline motifs containing the consensus
sequence PXXXPR (X= any aa) [92, 94]. They have also been shown to bind to ubiquitin ([13, 168].
The proline-rich region of CNI85 has been implicated to have an autoregulatory function. It can bind
to the first and second SH3 domain of CIN85 ([92, 17]. This intramolecular interaction can compete
with the SH3-domain-PRR-mediated interaction of CIN85 with PI3K p85-α [17]. The CC can mediate
homo-oligomerization of CIN85 as well as association with the CIN85-homolog CD2AP [189, 16, 48]. The
CC has also been described to mediate membrane association by phosphatidic acid (PA) binding [200].
CIN85 has been reported to interact with various proteins (reviewed in [64]). As adaptor protein, CIN85
is thought to exert its functions by bringing its interaction partners in spatial proximity. Mass spectro-
metric screens show that the CIN85 SH3 domains are redundant in their specificity [65, 20], at least under
in vitro conditions. Corresponding to this finding, it was shown biochemically that one CIN85 protein
can cluster several c-Cbl molecules [92]. While the knowledge of CIN85 structure and of its interaction
partners increased, the exact cellular functions of CIN85 were less clear and sometimes controversial.
The binding to SLP65 and c-Cbl was reported already in 2000 [189], and it was speculated that these
interactions might influence PLC-γ2 activity in B cells. Nevertheless, the focus of CIN85 function was on
its role for Epidermal growth factor receptor (EGFR) signaling for the next decade [166, 92, 91]. Upon
the c-Cbl-mediated recruitment of CIN85 to the activated EGFR, CIN85 is described to cluster c-Cbl
and endophilin molecules via interaction of their respective proline motifs with the CIN85 SH3 domains
[166]. By this mechanism, CIN85 recruitment has been shown to promotes receptor internalization of the
activated EGFR and other receptor tyrosine kinases [166, 131, 174]. However, the importance of CIN85
for EGFR endocytosis was negated by other reports ([63, 70, 77] and is regarded controversially (reviewed
in [64]). Besides the endocytotic processes itself, the intracellular trafficking of the endocytosed EGFR
has been reported to depend on SH3-mediated interactions of CIN85 with various interaction partners
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[199, 161]. Also CIN85-tyrosine phosphorylation has been reported to influence intracellular EGFR traf-
ficking [160].
The subcellular localization of CIN85 is still under dispute. CIN85 has been observed to be present in
endosomes, COPI-coated vesicles or peripheral structures as lamellipodia and invadopodia, depending
on the cell type and the CIN85 expression level [200, 63, 157, 117]. It is possible that the subcellular
localization of CIN85 is determined by its respective binding partners in the investigated model systems.
The functions attributed to CIN85 depend mainly on its ligands. Because many of them are known to
participate either in endocytosis or in Golgi-apparatus-linked vesicular transport, it is likely that CIN85
has an influence on these processes [64]. There have been some studies on the CIN85 function in immune
cells. CIN85 has been shown to interact with the cytoplasmic tail of the receptor CD2 [16]. In T cells,
CIN85 can link CD2 to the cytoskeleton by binding to the actin capping protein CapZ. This influences
potentially the TCR-induced cytoskeleton reorganization [71]. CIN85 has also been implicated to sta-
bilize CD2 expression at the plasma membrane [179]. In neutrophils, CIN85 has been reported to be
recruited to the activated FcγRIIa and to promote internalization and degradation of this receptor in a
c-Cbl dependent manner [107].
CIN85 has also been implicated in the signaling of the FcεRI in mast cells, a receptor that belongs to
the Multichain immune recognition receptor (MIRR) family, as BCR and TCR [134]. It was shown that
CIN85 contributes to endocytosis and intracellular trafficking of the FcεRI. Overexpression of CIN85
accelerated the FcεRI internalization, impairing the FcεRI-mediated degranulation of mast cells [112].
Furthermore, CIN85-overexpression reduced the level of Syk in mast cells, thereby diminishing also PLC-
γ phosphorylation and Ca2+ influx upon FcεRI stimulation. [130]. In contrast to the inhibitory effect of
CIN85 on the FcεRI, the knockdown of CIN85 in the chicken B cell line DT40 led to an impaired BCR
signaling, especially if it was done in cells deficient for the CIN85 homolog CD2AP [121]. This suggests
that CIN85 might be a positive regulator in BCR signaling. No effect of CIN85 on BCR endocytosis
was found [119, 18]. It has further been demonstrated that CIN85 interacts with the phosphatase SHIP1
in B cells, leading to the hypothesis that CIN85 might downregulate BCR signaling by recruiting this
negative regulator to the activated BCR [20].
So the overall image of existing literature suggested that CIN85 might be a negative as well as a positive
regulator of BCR signaling. Nevertheless, it was clear that the interaction of CIN85 with SLP65 had an
enhancing effect on the BCR signaling cascade [121]. The aim of my doctoral thesis was to elucidate the
mechanism by which CIN85 supports SLP65, gaining thereby general insight into the CIN85 function.
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2.6 Aim of this study
Plasma membrane recruitment and phosphorylation of the adaptor protein SLP65 are crucial key steps
of the BCR signaling and hence efficient B cell activation. These processes have been shown to depend
on the interaction of SLP65 with the other adaptor protein CIN85. Nevertheless, it was totally unclear
how the interaction with CIN85 contributes to SLP65 function. The aim of my doctoral thesis was the
elucidation of the molecular mechanism by which CIN85 supports the function of SLP65 in BCR signaling.
To get inside into CIN85 function in B cells, I dealt with the following specific questions:
1. Does CIN85 possess protein or lipid ligands to target SLP65 to specific subcellular compartments?
The CIN85 protein interactome was investigated by mass spectrometric analysis. Membrane association
was assessed by subcellular fractionation experiments and lipid binding studies.
2. Which domains of CIN85 are essential for its support of SLP65? Can CIN85 binding be substituted by
equipping SLP65 directly with additional functional domains? These points were addressed genetically
by the generation of chimeric proteins and subsequent analysis of their functionality in the BCR pathway.
3. Can the structure of CIN85 explain its function? The structure of the C-terminal CIN85 coiled-
coil domain was elucidated in cooperation with Prof. C. Griesinger’s group . With this knowledge, the
influence of single amino acids for CIN85 function could be examined.
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3 Material and methods
3.1 Material
3.1.1 Instruments
Tab. 3.1: Instruments used in this study
Name Manufacturer
Agarose Gelelectrophoresis System Peqlab
Balance BP61 Sartorius
Balance H95 Sartorius
Balch homogenizer MPI BPC, Göttingen
BioPhotometer Eppendorf
Cell culture incubator HeraCell 150 CO2 Heraeus
Cell disruption vessel 45 ml Parr Instrument
Chemi Lux Gel Imager Intas Science Imaging
Confocal laser scanning microscope TCS SP2 Leica Microsystems
Countess cell counter Invitrogen
Electrophoresis power supply EPS 301 Amersham BioSciences
Electrophoresis System Hoefer SE600 Amersham
Flow cytometer LSR II Becton Dickinson
Freezer Platilab 340 Angelantoni Industrie
GenePulser II electroporation system Bio-Rad Laboratories
Ice machine Ziegra
Incubation shaker Unitron Infors
Incubator Kelvitron t Heraeus
Laminar flow cabinet HERA safe Heraeus
Light microscope TELAVAL 31 Zeiss
LSR II BD Biosciences




Microplate reader PowerWave 340 BioTek
Mini PROTEAN Tetra Cell Bio-Rad
Multifuge 3SR Heraeus
NanoDrop 2000 Thermo Scientific
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Rotor SW40 Ti Beckman
Rotor SW41 Ti Beckman
Semiphor Transphor Unit TE77 Amersham Bioscience
Shaker 3006 GFL
Sonicator Bandelin Sonoplus
Sorvall RC 3B Plus Sorvall
Thermomixer comfort Eppendorf
Ultracentrifuge Optima L-70k Beckman
Ultracentrifuge Optima LE 80k Beckman
UV-illuminator Intas systems
Vortex Genie 2 Scientific industries
Water bath GFL
Water Purification System Milli-Q Millipore, Sartorius
3.1.2 Software
Tab. 3.2: Software used in this study
Name Manufacturer Application
Chemostar professional Intas Immunoblot documentation
Coreldraw Corel Corporation Graphic editing
FACSDiva BD Biosciences Flow cytometry recording
Flowjo Treestar Flow cytometry analysis
ImageJ W. Rasband Image processing
Leica confocal software Leica Microscopy image processing
LaTeX L. Lamport Text processing
Microsoft office2010 Microsoft Text processing
pDraw32 Acaclone software DNA sequence information processing
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3.1.3 Consumables
Tab. 3.3: Consumables used in this study
Name Manufacturer
Blotting Paper Whatman GE Healthcare
CELLSTAR 96 well suspension culture plates Greiner bio-one
CELLSTAR dishes 60 mm, 100 mm, 145 mm Greiner bio-one
CELLSTAR serological pipettes 2 ml, 5 ml, 10 ml, 25 ml Greiner bio-one
CELLSTAR tubes, 15 ml, 50 ml Greiner bio-one
Cyro.S tubes Greiner bio-one
Dialysis tubing SERVAPOR Serva
Dishes for bacteria, 92 mM Sarstedt
Filter tips Greiner bio-one
Microscope imaging chambers, 4 wells Lab Tek
Nitrocellulose membrane Hybond ECL Amersham Biosciences
Parafilm American National Can
PCR tubes, 0.2 ml Sarstedt
Photometer cuvettes Roth
Pierce centrifuge columns Thermo scientific
Pipette tips Greiner bio-one
Reaction tubes, 1.5 ml, 2 ml Greiner bio-one
Scalpel B. Braun
Sterile filter Filtropur, S 0.2 and S 0.45 Sarstedt
Syringe Omnifix ,1 ml B. Braun
Syringes, 5 ml, 10 ml BD Biosciences
Tubes for flow cytometry, 5 ml Sarstedt
Tubes, 14 ml Greiner bio-one
Ultracentrifugation tubes 9/16 x 3 3/4” Beckman
Vivaspin 500 Sartorius
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3.1.4 Chemicals and reagents
Tab. 3.4: Chemicals and reagents used in this study
Name Manufacturer
Acetic acid (HOAc) Roth
Acrylamide/bis-Acrylamide Rotiphorese Gel 30 Roth
Agar-Agar Roth
Agarose Peqlab
Ammonium persulfate (APS) Roth
Ampcillin Roth
L-Arginine:HCl (13C6) Cambridge Isotope Lab.
Bleomycin (Bleocin) Merck
Bovine serum albumin (BSA) Serva
Brom-chlor-indoxyl-β-D-galactosid (X-gal) Roth
Bromophenol blue Merck
Bovine serum albumin (BSA) solution NEB
Calcium chloride (CaCl2) Merck
Chicken serum Sigma
Coomassie Brilliant Blue R-250 Roth
Dimethyl sulfoxide (DMSO) Roth
DNA Ladder GeneRuler 1kb Fermentas
Deoxynucleoside triphosphate (dNTP) mix NEB
Dithiothreitol (DTT) Roth
n-Dodecyl β-D-maltoside Sigma-Aldrich
Ethylenediaminetetraacetic acid (EDTA) Roth
Ethanol Roth
Ethidium Bromide Roth
Fetal Calf Serum (FCS), dialyzed PAN Biotech




Hydrogen peroxide (H2O2) Roth
Hydrochloric acid (HCl) Roth
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth
Hexadimethrine bromide (polybrene) Sigma-Aldrich
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Name Manufacturer
Igepal CA-630 (NP40) Sigma-Aldrich
Immersion oil Merck
INDO-1 AM Life technologies





L-Lysine:2HCl (4,4,5,5-D4) Cambridge Isotope Lab.
µMACS GFP Tagged Protein Isolation kit Miltenyi
Magnesium acetate (Mg(OAc)2) Roth
Magnesium chloride (MgCl2) Roth
Methanol (MeOH) Roth
NEBuffers 1,2,3,4,cut smart NEB
NuPAGE LDS sample buffer Invitrogen
NuPAGE sample reducing reagent Invitrogen
Phosphatidic acid (PA) coated beads Echelon
p-Coumaric acid Sigma-Aldrich
Penicillin Sigma-Aldrich
Phusion HF reaction buffer NEB
Pluronic F-127 Life technologies
Potassium chloride (KCl) Roth
Potassium dihydrogen phosphate (KH2PO4) Merck
Prestained Protein Marker Broad Range NEB
Protease Inhibitor Cocktail P2714 Sigma-Aldrich
Protein A/G agarose beads Santa Cruz
Protino Ni-IDA 1000 Macherey-Nagel
Pure Yield Plasmid Midiprep System Promega
Puromycin InvivoGEN
Sodium acetate (NaOAc) Roth
Sodium azide (NaN3) Roth
Sodium chloride (NaCl) Roth
Sodium dodecyl sulfate (SDS) Roth
Sodium fluoride (NaF) Roth
di-Sodium hydrogen phosphate (Na2HPO4) Roth
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Name Manufacturer
Sodium hydroxide (NaOH) Roth
Sodium orthovanadate (Na3VO4) Sigma-Aldrich
Strep-Tactin Superflow high capacity IBA
Strep-tag elution buffer IBA
Streptomycin Sigma-Aldrich
Sucrose Roth
T4 DNA Ligase buffer NEB
Tetramethylethylenediamine (TEMED) Roth







Wizard SV Gel and PCR clean up Kit Promega
Yeast extract Roth
3.1.5 Buffers and solutions
Tab. 3.5: Buffers and solutions used in this study. All %-indications refer to weight per volume.
Name Composition
Antibody dilution solution 1% BSA, 0.01% NaNa3 in TBS-T
Blotting buffer 48 mM Tris, 39 mM glycine, 0.0375% SDS, 0.001% NaN3,
20% MeOH
Cell lysis buffer 50 mM Tris, 50 mM NaCl, 5 mM NaF, 1 mM Na3VO4, 1:50
Protease Inhibitor, 0.5% NP40, pH 8.0
Cell lysis buffer for strep-tag AP Cell lysis buffer + 0.5% n-dodecyl β-D-maltoside
Coomassie staining solution 40% MeOH, 10% HOAc, 0.1% Coomassie Brilliant Blue
R-250
DNA loading buffer (6x) 60 mM EDTA, 10 mM Tris/HCl, 60% glycerol, 0.03%
Bromophenol blue, pH 7.6
ECL solution composition 4 ml ECL solution A, 400µl ECL solution B, 1.2 µl H2O2
(30%)
ECL solution SA 100 mM Tris/HCl, 0.28 mM Luminol, pH 8.6
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Name Composition
ECL solution SB 6.7 mM p-coumaric acid in 100% DMSO
Homogenization buffer 250 mM Sucrose, 20 mM KCl, 25 mM HEPES, 2.5 mM
Mg(OAc)2, 2.5 mM DTT, 1:50 Protease Inhibitor, pH 7.4
Krebs-Ringer solution with
CaCl2
140 mM NaCl, 10 mM D-Glucose, 10 mM HEPES, 4 mM
KCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.4
Laemmli loading buffer (5x) 500 mM DTT, 150 mM Tris/HCl, 50% Glycerol, 15% SDS,
0.05% Bromophenol blue, pH 6.8
Lew buffer 300 mM NaCl, 50 mM NaH2PO4, pH 8.0
PBS 137 mM NaCl, 2.4 mM KCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4, pH 7.4
Resolving gel solution 375 mM Tris/HCl, 10% Acrylamide/bis-Acrylamide, 0.1%
APS, 0.1% TEMED, pH 8.8
SDS-PAGE running buffer 192 mM glycine, 25 mM Tris, 0.1% SDS
Stacking gel solution 125 mM Tris/HCl, 4.8% Acrylamide/bis-Acrylamide, 0.1%
APS, 0.1% TEMED, pH 6.8
TAE buffer 40 mM Tris/HOAc, 10 mM NaOAc, 1 mM EDTA, pH 7.8
TBS-T 137 mM NaCl, 20 mM Tris, 0.1% Tween20, pH 7.6
Western blot blocking solution 5% BSA, 0.01% NaN3 in TBS-T
3.1.6 Antibodies
Tab. 3.6: Antibodies used in this study
Name Manufacturer
α-Akt, rabbit monoclonal (C73H10) Cell signaling technologies
α-Blnk, mouse monoclonal (2B11) BD Biosciences
α-chicken IgM, mouse (M4) Bethyl Laboratories
α-CIN85, rabbit polyclonal (C6115) Sigma-Aldrich
α-Clathrin heavy chain, mouse monoclonal (23/Clathrin) BD Biosciences
α-GFP, mouse monoclonal (7.1+13.1) Roche
α-GM130, mouse monoclonal (35/GM130) BD Biosciences
α-Grb2, mouse monoclonal (81/GRB2) BD Biosciences
α-HA, rat monoclonal (3F10) Roche
α-human IgM, F(ab’)2 Fragment, mouse Jackson Immune Research Lab.
α-LAMP1, mouse monoclonal (H4A3) BD Biosciences
α-Lyn, mouse monoclonal (42/Lyn) BD Biosciences
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Name Manufacturer
α-Rab5, mouse monoclonal (621.1) Synaptic Systems
α-α-Tubulin, mouse monoclonal (B512) Sigma-Aldrich
α-VAMP7, rabbit polyclonal (LS-B88839) LifeSpan BioSciences
α-mouse IgG (HRP-conjugated), goat Southern biotech
α-rabbit IgG (HRP-conjugated), goat Southern biotech
3.1.7 Enzymes
Tab. 3.7: Enzymes used in this study
Name Manufacturer
AgeI HF NEB








Phusion High-Fidelity DNA Polymerase NEB
PvuI NEB
T4 DNA ligase NEB
Taq PCR Master Mix Qiagen
XhoI NEB
3.1.8 Media




SILAC RPMI-1640 Medium Thermo Scientific
Lysogeny broth (LB medium) 10 g/L trypton/Pepton, 5 g/L yeast extract,
10 g/L NaCl
LB-Agar 15 g Agar-Agar in 1L LB medium
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3.1.9 PCR Primers
Tab. 3.9: Oligonucleotides used as PCR primers in this study. All oligonucleotides were manu-
factured by MWG-Biotech.
Name Sequence
BglII SLP65 fw TAATAGATCT CGACAAGCTT AATAAAATAA
CCGTCC
CD2AP CC fw Bam TTCAGGATCC CATGGAAATC AAAGCTAAAG
TGGA
CD2AP CC Nde fw TTCACATATG ATGGAAATCA AAGCTAAAG
CD2AP rev Bam ME frame AAAAAAGCTG TCCTGTCTTC GGATCCACTT
Cin CC 631 Not rev TATGCGGCCG CTCATTTCTG CTGGTCCTTC
ATGGTCT
Cin CC 632 Bgl fw TTCAAGATCT CATGCGAGAG ATTAAACAGT
TATTGTCT
Cin CC Bam 631 rev CGAGGGATCC TTCTGCTGGT CCTTCATGGT CT
Cin CC Bgl fw TTCAAGATCT CATGGAAGGA AAACCAAAGA
TGGAGCCT
Cin PR/CC Not rev with stop ATGCGGCCGC TCATTTTGAT TGTAGAGCTT
TCTT
CIN85 CC fw Nde TTCGCATATG GAAGGAAAAC CAAAGATGGA
GCCT
CIN85 CC fwd Bam AAAGGATCCA CCATGGAAGG AAAACCAAAG
ATGGAGCCT
CIN85 CC rev Xho with stop TTCGCTCGAG TTATTTGATT GTAGAGCTTT CTT
Cin85 PR/CC Bam fw TTCGTGGATC CCATGGACTT TGAAAAGGAA GGG
Cin85 PR/CC Rev CGAGGGATCC TTTGATTGTA GAGCTTTCTT
Cin85 SH3 rev CGAGGGATCC GGTGGAAGTA ACTTCACGAA
Cin85SH3 ATG Blg fw TTCGTAGATC TCATGGTGGA GGCCATAGTG GA
CinCC L619A fw ACACAGGTCC GCGAGGCGAG GAGCATCATC
GAGAC
CinCC L619A rev GTCTCGATGA TGCTCCTCGC CTCGCGGACC
TGTGT
CinCC L619K fw ACACAGGTCC GCGAGAAGAG GAGCATCATC
GAGAC
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Name Sequence
CinCC L619K rev GTCTCGATGA TGCTCCTCTT CTCGCGGACC
TGTGT
CinPR Bam rev CGAGGGATCC ATCTTTGGTT TTCCTTCCGT
HAtag Cin CC Bgl fw TTCAAGATCT CATGTACCCA TACGACGTCC
CAGACTACGC TGAAGGAAAA CCAAAGATGG
AGCCT
hSlp rev stop Xho TTCTCTCGAG TTATGAAACT TTAACTGCAT




NotI SLP65 rev TAATGCGGCC GCTTATGAAA CTTTAACTGC
ATACTTCAG
Overlap slpCinCC 632 fw AAGTATGCAG TTAAAGTTTC ACGAGAGATT
AAACAGTTAT TGTCT
Overlap slpCinCC632 rev AGACAATAAC TGTTTAATCT CTCGTGAAAC
TTTAACTGCA TACTT
pEGFPN1 for GTCGTAACAA CTCCGCCC
pEGFPN1 rev GTCCAGCTCG ACCAGGATG
pMSCVfw CCCTTGAACC TCCTCGTTCG ACC
pMSCVrev CAGACGTGCT ACTTCCATTT GTC
Raf1 PA Bam fw TTCAGGATCC CATGAGGAAT GAGGTGGCTG
TTCT
Raf1 PA Bam rev TGAAGGATCC CCTGATCCCT CGCACCACTG
GGTCAC
SCOC CC Bam fw TTCAGGATCC CATGATGAAT GCCGACATGG AT
SCOC CC Bam rev TGAAGGATCC TTACGTTTGG ATTTGGTATC G
SCOC E93V K97L fwd GCCGAAAATC AGGTGGTACT GGAGGAATTA
ACCCGTCTGA TCAAC
SCOC E93V K97L rev GTTGATCAGA CGGGTTAATT CCTCCAGTAC
CACCTGATTT TCGGC
SCOC N125L N132V fw TGCCGTAAAA GAGGAGCTTC TGAAACTGAA
AAGTGAGGTT CAAGTGCTGG GC
SCOC N125L N132V rev GCCCAGCACT TGAACCTCAC TTTTCAGTTT
CAGAAGCTCC TCTTTTACGG CA
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Name Sequence
Slp dN (46) Bam ATG fw TTCGGGATCC CATGAGTGTT CCTCGAAGGG
ACTACG
Slp dN (46) Bgl ATG fw TTCGAGATCT CATGAGTGTT CCTCGAAGGG
ACTACG
Slp EcoRI rev AAGTGAATTC TTATGAAACT TTAACTGCAT A
SLP65CIN85CC OL fw AAGTATGCAG TTAAAGTTTC AGAAGGAAAA
CCAAAGATGG AGCCT
SLP65CIN85CC OL rev AGGCTCCATC TTTGGTTTTC CTTCTGAAAC
TTTAACTGCA TACTT
SLP65CIN85PRR OL fw AAGTATGCAG TTAAAGTTTC AGACTTTGAA
AAGGAAGGGA AT
SLP65CIN85PRR OL rev ATTCCCTTCC TTTTCAAAGT CTGAAACTTT
AACTGCATAC TT
Slp76 Age rev TGAAACCGGT GGGTACCCTG CAGCATGCGT TAA
Slp76 Bam fw TTCAGGATCC CGCACTGAGG AATGTGCCC
slpdN Bam fw frVB TTCAGGATCC AGTGTTCCTC GAAGGGACTA CG
Slprev fl Xho mit Stop TTCGCTCGAG TTATGAAACT TTAACTGCAT A
T7 TAATACGACT CACTATAGG
3.1.10 Plasmids
Tab. 3.10: Basic plasmids used in this study
Name Source,description Application
pCit-N1 Dr. M. Engelke, based on
pEGFP-N1 (BD Biosciences
Clontech), eGFP exchanged for
Citrine
Cloning, addition of Citrine
tag to chimeric proteins
pET 16b TEV Dr. S. Becker Expression of recombinant
His-tagged proteins
pCR2.1 Invitrogen TA cloning
pABESpuro N-One-Strep Dr. V. Bremes Expression of electroporated
cDNA in eukaryotic cells,
includes N-terminal strep-tag
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Name Source,description Application





Dr. M. Engelke, based on









for bleomycin resistance cassette





pMSCV puro NCit Dr. M. Engelke, based on





Tab. 3.11: Plasmid constructs used in this study. All proteins originated from human, with
exception of VAMP7 (chicken). The plasmid were prepared for this thesis, if not indicated
otherwise. The numbers indicate the amino acid position in the protein. General abbreviations:
SLP65-∆N means SLP65 aa 46-456. SLP65-M2,3 means SLP65 with amino acid exchanges
R247A and R312A.
Name Description Source
pCitN1 SLP65-∆N SLP65-∆N, C-terminal Citrine
tag
pCitN1 SLP65-∆N-M2,3 SLP65-∆N-M2,3, C-terminal
Citrine tag
pCitN1 SLP65-M2,3 SLP65-M2,3, C-terminal Citrine
tag
pCitN1 SLP65-wt SLP65-wt, C-terminal Citrine
tag
pCitN1 SLP65-∆N RL SLP65-∆N R372L, C-terminal
Citrine
Dr. M. Engelke
pCitN1 SLP76 SLP76, C-terminal Citrine
pABES puro N-OneStrep
CD2AP
N-terminal Strep tag, CD2AP Dr. V. Bremes
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N-terminal Strep tag, CIN85 Dr. V. Bremes
pABES puro N-OneStrep
CIN85 CC SLP65-∆N
N-terminal Strep tag, CIN85
594-665, SLP65-∆N
pCR2.1 CD2AP CC CD2AP 568-639












pCR2.1 CIN85 PRR CIN85 329-599
pCR2.1 CIN85 PRR/CC CIN85 329-665
pCR2.1 CIN85 SH3 CIN85 1-328
pCR2.1 Raf PA Raf1 391-426
pCR2.1 SCOC CC SCOC 78-159
pCR2.1 SCOC CC Tetramer SCOC 78-159 N125L/N132V
pCR2.1 SCOC CC Trimer SCOC 78-159 E93V/K97L
pET16b CD2AP CC
SLP65-∆N
N-terminal His tag, CD2AP
568-639, SLP65-∆N
pET16b CIN85 CC N-terminal His tag, CIN85
594-665
pET16b CIN85 CC L619K N-terminal His tag, CIN85
594-665 L619K
pET16b CIN85 CC L619K
SLP65-∆N




N-terminal His tag, CIN85
594-665, SLP65-∆N
pET16b SLP65-∆N N-terminal His tag, SLP65-∆N S. Pirkuliyeva
pET16b SLP65-wt N-terminal His tag, SLP65-wt S. Pirkuliyeva
pET28a SCOC CC Strep
Tag
SCOC 78-159, C-terminal Strep
tag
Dr. K. Kühnel
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Name Description Source
pMSCV bleo HA CIN85 CC
L619K SLP65-∆N-M2,3
N-terminal HA tag, CIN85
594-665 L619K,
SLP65-∆N-M2,3
pMSCV bleo HA CIN85 CC
SLP65-∆N-M2,3








pMSCV bleo VC Venus 156-239 Dr. M. Engelke

















pMSCV puro CD2AP CC CD2AP 568-639






pMSCV puro CIN85 CC
594-631
CIN85 594-631






pMSCV puro CIN85 CC
632-665
CIN85 632-665
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pMSCV puro CIN85 SH3 CIN85 1-328
pMSCV puro CIN85CC
L619K SLP76




























































pMSCV puro PH SLP65-∆N
CCit







pMSCV puro PLC d PH PLC-δ PH domain Dr. M. Engelke
pMSCV puro Raf PA
SLP65-∆N
Raf1 391-426, SLP65-∆N








pMSCV puro SCOC CC
Tetramer
SCOC 78-159 N125L/N132V









pMSCV puro SCOC CC
Trimer
SCOC 78-159 E93V/K97L
pMSCV puro SCOC CC SCOC 78-159
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pMSCV puro SLP65-wt CCit SLP65-wt, C-terminal Citrine
tag
pMSCV puro Syk tSH2 Syk tSH2 domains Dr. M. Engelke
pMSCV puro SyktSH2 ∆N
CCit







pMSCV puro VN Venus 1-173 Dr. M. Engelke
pMSCV puro VN SLP65-∆N
RL
Venus 1-173, SLP65-∆N R372L





Tab. 3.12: Bacterial strains used in this study
Strain Manufacturer
One Shot TOP10F’ chemo-competent E. coli Life technologies
One Shot BL21 (DE3) chemo-competent E. coli Life technologies
3.1.12 Eukaryotic cell lines
DT40 (ATCC CRL-2111)
DT40 is a chicken B cell line which derived from an avian leucosis virus-induced bursal lymphoma [6].
This cell line displays IgM on the cell surface and shows a high ratio of targeted to random DNA inte-
gration. This facilitates genetic modification via homologous recombination [194].
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Ramos (DSMZ: ACC 603)
The Ramos B cell line is established from the ascitic fluid of a 3-year-old boy with Burkitt lymphoma
in 1972 [86]. The cell line displays IgM paired with a λ light chain on its surface. It is Epstein-Barr
virus-negative.
Platinum-E
Platinum-E is a HEK 293T-derived retroviral packaging cell line [114]. It expresses the structural genes




Molecular cloning techniques were performed according to established standard protocols as described in
Sambrook and Russell [152] if not indicated otherwise.
3.2.1.1 Polymerase chain reaction (PCR)
PCR, originally described in Mullis et al. [115], was used to amplify DNA fragments for following
cloning procedures. The enzyme Phusion High-Fidelity polymerase (NEB) was used to catalyze the
PCR. The reaction mixture was composed according to the instructions given in the manufacturer’s
manual. A 20 µl reaction mixture contained 4µl Phusion HF reaction buffer, dNTPs (0.2 mM), DNA
oligonucleotides as primers (1µM of each primer), 25-100 ng DNA template and 0.4 U Phusion High-
Fidelity DNA polymerase. The indicated standard temperature protocol was used (Table 3.13). For
GC-rich templates, the annealing temperature was increased to 60-65.
Tab. 3.13: Temperature gradient used for PCR
Step Temperature [] Time Number of cycles
Initial denaturation 98 2 min 1
Denaturation 98 15 s 30-32
Annealing 55 30 s 30-32
Elongation 72 20 s/kB 30-32
Final elongation 72 10 min 1
3.2.1.2 Overlap extension PCR
Overlap extension PCR, a PCR variant to fuse two DNA fragments [68], was used to create DNA
constructs encoding for chimeric or tagged proteins. First, two fragments were amplified by PCR as
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described above. The primers for these two PCRs were designed to create an overlap between the
fragments. After their isolation by agarose gel electrophoresis and following DNA purification, the two
fragments were mixed and served as primers for each other in a following PCR of 15 cycles. Subsequently,
primers corresponding to beginning and end of the final product were added at a concentration of 1 µM
and a PCR of 20 cycles was launched. The annealing temperature of this final PCR was set to 60 to
increase the specificity.
3.2.1.3 Site directed mutagenesis
The plasmid pCR2.1, which is optimized for cloning procedures, was used for mutagenesis reactions. The
protocol was based on the QuikChange method (Stratagene) with modifications according to Edelheit et
al. [36]. Two standard PCRs were carried out, one with a forward primer carrying the desired mutation,
the other with the complementary reverse primer. The elongation time was chosen to allow a complete
amplification of the plasmid. In the end, both reaction mixtures were combined and de- and re-natured
according to the indicated temperature protocol (Table 3.14). The reaction mixture was digested with
DpnI and transformed into the E. coli strain Top10F’ (see 3.2.1.8)










3.2.1.4 Enzymatic digest of DNA
For following cloning procedures, DNA originating from PCRs or Plasmids was digested using type
II restriction enzymes (NEB). Therefore, approx. 1 µg DNA was mixed with 0.5 µl of each restriction
enzyme, the NEB buffer and BSA (final concentration 0.1µg/µL). Water was added to a final reaction
volume of 25µL. The digest was performed for 2-16 h.
3.2.1.5 Agarose gel electrophoresis
To separate DNA fragments according to their size, agarose gel electrophoresis was used. 1% or 2%
agarose gels were prepared in TAE buffer, 1 µg/mL ethidium bromide was added. The DNA containing
samples were mixed with DNA loading buffer and loaded on the agarose gel. To estimate the DNA frag-
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ment size, the DNA marker GeneRuler 1kb (Fermentas) was loaded on a lane next to the samples. The
electrophoresis was performed at 100 V for 30-40 min (15 min for DNA fragments smaller than 300 bp) in
TAE buffer. The DNA was visualized on an UV-illuminator.
3.2.1.6 Purification of DNA from agarose gels or PCR reactions
The purification of DNA fragments from PCR or agarose gels was performed using the Wizard SV Gel
and PCR Clean-Up-Kit (Promega), following the manufacturer’s instructions.
3.2.1.7 Ligation of DNA fragments
For the ligation of DNA fragments cut with restriction enzymes, 6.5µl of the insert were mixed with
2 µl of the vector (cut plasmid), 1µl T4 DNA ligase buffer (NEB) and 0.5µl T4 DNA ligase (NEB). The
reaction was incubated for 1 h at room temperature or overnight at 16. Undigested PCR products
were ligated in the vector pCR2.1 by ”TA”-cloning. A-overhangs were generated by incubating the PCR
product with Taq PCR master mix at 72 for 20 min. Subsequently, 2 µl of the PCR product (containing
A-overhangs) were mixed with 1µl of linear pCR2.1 vector, 0.5 µl T4 DNA ligase and 1µl T4 DNA ligase
buffer and 4.5µl H2O. The ligation was incubated for 1 h at room temperature.
3.2.1.8 Transformation
2-5 µl of the ligation reaction were added to 50 µl chemocompetent E. coli Top10F’. After 30 min incuba-
tion on ice, the bacteria were incubated at 42 for 42 s, put on ice for 2 min and incubated at 37 for
30 min. Afterwards, they were plated of LB-agar dishes containing either Ampicillin (for pCR2.1, pM-
SCV, pABES and pET16b plasmids) or Kanamycin (for pCitN1 and pHCMV plasmids) and incubated
at 37 for 12-16 h.
3.2.1.9 Preparation of plasmid DNA
Mini Preparation
The preparation of plasmid DNA in small scale was performed using the Invisorb Spin Plasmid Mini
Two-kit (Invitek) according to the manufacturer’s instructions. Shortly, the 4 ml bacterial cultures were
grown overnight, the bacteria were pelleted and lysed by SDS/NaOH. The plasmid DNA was bound to
a spin column and washed with buffer containing ethanol. The DNA was eluted with 50 µl nuclease-free
water, the DNA concentration was spectrometrically determined using the Nanodrop system.
Midi Preparation
The preparation of plasmid DNA in medium scale was performed using the PureYield Plasmid Midiprep-
kit (Promega) according to the manufacturer’s instructions. 50 ml bacterial cultures were grown overnight,
the remaining procedure resembled the Mini preparation procedure. The DNA was eluted with 400µl
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nuclease-free water.
3.2.2 Cell biological methods
3.2.2.1 Culturing of eukaryotic cells
The B cell lines DT40 and Ramos were cultured in RPMI-1640 medium, supplied with 10% FCS and
Penicillin/Streptomycin. For the culturing of the DT40 cells, 5% chicken serum were additionally added.
The cells were cultured at 37 and a CO2 concentration of 5%. The retroviral packaging cell line
Platinum-E was cultured in DMEM, supplied with 10% FCS and Penicillin/Streptomycin.
3.2.2.2 Freezing and thawing of eukaryotic cells
To freeze DT40, Ramos or Platinum-E cells, 5·106-2·107 cells were pelleted (300 g, 4 min), resuspended in
1 ml freezing medium (FCS + 10% DMSO), and frozen at -140. To thaw DT40, Ramos or Platinum-E
cells, the frozen cells were thawed at 37 for 3 min and transferred into 10 ml cell culture medium. To
reduce the DMSO concentration, the cells were pelleted (300 g, 4 min) and resuspended in 10 ml culture
medium before further culturing.
3.2.2.3 SILAC labeling
The introduction of heavy labeled amino acids in the B cell lines DT40 and Ramos was performed ac-
cording to Oellerich et al., 2009 [122]. The cells were cultured in SILAC RPMI-1640 medium containing
0.12 mM L-arginine (13C6) (+6) and 0.27 mM L-lysine (4,4,5,5-D4) (+4), 10% dialyzed FCS and Peni-
cillin/Streptomycin. To achieve a complete labeling, the cells were cultured in this medium for at least 7
days. The unlabeled control cells were cultured in RPMI-1640 medium supplied with 10% dialyzed FCS
and Penicillin/Streptomycin.
3.2.2.4 Retroviral transduction
A retroviral transduction system, described in Stork et al. [169], was used to integrate plasmid DNA stably
in the genomic DNA of the DT40 B cell line. Retroviral particles were generated using the Platinum-E
cell line. For the transfection of Platinum-E cells, 250µl RPMI-1640 medium (serum free) were mixed
with 8µl TransIT-293 transfection reagent (Mirus). After 15 min incubation at room temperature, 1.7 µg
plasmid DNA, coding for the protein of interest, and 0.5 µg of the plasmid pHCMV-VSV-G, coding for the
envelope glycoprotein of VSV, were added. The mixture was incubated at room temperature for 20 min.
The medium of a dish with Platinum-E cells (70-80% confluent) was removed and substituted with 2.5 ml
of RPMI-1640 medium (10% FCS); afterwards the transfection mixture was added slowly. On the next
day, 1.5 ml RPMI-1640 medium were added. On the second day after transfection, 1·106 DT40 cells were
resuspended in 2 ml fresh RPMI-1640 medium, the supernatant of the Platinum-E culture, containing the
retroviral particles, was added. To increase the efficiency of the retroviral infection, polybrene was added
to a final concentration of 3 µg/ml. The medium was changed the next day to remove the polybrene.
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The selection of successfully transduced cells started one day later. For DT40 cell, 1 µg/ml puromycin
for 3 days respectively 50µg/ml bleomycin for 2 days were used.
3.2.2.5 Transfection of eukaryotic B cells by Electroporation
Electroporation was used to introduce DNA stably in the genome of the B cell lines DT40 and Ramos
as described in Oellerich et al. [122]. 1·107 cells were pelleted (300 g, 4 min) and resuspended in 700 µl
PBS. 25 µg of the linearized DNA (plasmid pABESpuro) were added. The mixture was transferred to an
electroporation cuvette and incubated on ice for 10 min. The electroporation was performed at 270 V and
960 µF. After incubation on ice for 10 min, the cells were resuspended in culture medium and incubated
for 24 h at 37. Afterwards, the culture medium was changed and successfully transfected cells were
selected with puromycin at a concentration of 1 µg/ml (DT40) or 0.5 µg/ml (Ramos). To isolate single
clones, the cells were plated on 96 well culture plates. After 10-14 days of antibiotic selection, clones were
transferred in 60 mm cell culture dishes and screened by immunoblotting for production of the protein
corresponding to the transfected DNA.
3.2.3 Biochemical methods
3.2.3.1 Preparation of cell lysates
Lysates of DT40 cells were prepared as described in Stork et al. [169]. DT40 cells were pelleted (300 g,
4 min), washed once with PBS, and counted. They were resuspended in 20 µl Lysis buffer (containing
0.5% NP40) per 1·106 cells and lysed on ice for 1 h. The nuclei were pelleted by centrifugation (16,000 g,
20 min, 4), the supernatant, constituting the lysate, was transferred to subsequent applications (e.g.
affinity purification, immunoblot analysis).
3.2.3.2 Affinity purification
For SILAC-based mass spectrometric analyses, Strep-tagged Proteins were purified using the Step-tag-
Streptactin interaction as described in Oellerich et al., [121]. Cell lysates of 5·107-2·108 cells were prepared
as described above (see 3.2.3.1), the lysis buffer contained additionally 0.5% n-dodecyl β-D-maltoside. The
following purification was carried out at 4 to avoid protein degradation. The cell lysate was transferred
to a column containing 200µl Strep-Tactin Superflow beads (equilibrated in lysis buffer) and incubated
overnight. After the flowthrough was removed, the beads within the column were washed five times with
1 ml lysis buffer. The internal column volume was overcome by adding 100µl Strep-tag elution buffer
(1x). Afterwards, the column was closed and incubated for 30 min with 500µl Strep-tag elution buffer
(1x).The elution fraction was collected. 200 µl Strep-tag elution buffer (1x) were added to the column to
collect remaining eluting proteins. The elution fraction was concentrated to 50 µl by a Vivaspin 500 col-
umn (cut-off 10 kDa). LDS sample buffer and reducing agent were added, the sample was incubated for
10 min at 70. To allow SILAC quantification, two samples, one unlabeled and one R+6, L+4 labeled,
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were combined at 1:1 ratio. The samples were analyzed by mass spectrometry in Prof. H. Urlaub’s group.
To assess the association of proteins to phosphatidic acid (PA), a precipitation assay based on PA-
coated beads was used. 20µl of PA-coated beads were added to 5µg of recombinant protein in 1 ml LEW
buffer, the mixture was incubated for 1 h at 4. The beads were precipitated (350 g, 4 min, 4), the
supernatant was discarded. After three washing steps with 1 ml LEW buffer, the proteins attached to the
PA-coated beads were eluted by addition of 50 µl Laemmli-buffer (1x) and incubation at 90for 10 min.
The sample was analyzed by immunoblotting.
3.2.3.3 VAMP7+ vesicle enrichment
VAMP7+ vesicles were enriched using the µMACS GFP Tagged Protein Isolation kit (Miltenyi) according
to the manufacturer’s instructions. 2·108 DT40 cells expressing Cerulean-tagged VAMP7 were disrupted
by passing a Balch homogenizer as described for subcellular fractionation (see 3.2.3.5). The PNS was
mixed with 50 µl α-GFP MicroBeads and incubated for 30 min one ice. A µMACS column was placed in a
static magnet field and equilibrated first with ethanol (70%), then with homogenization buffer. The PNS-
bead mixture was applied on the column, the column was washed five times with 1 ml homogenization
buffer. Subsequently, 20 µl pre-heated Laemmli or NuPAGE LDS sample buffer (95) were applied to
overcome the internal column volume, the column was incubated for 5 min. To elute proteins attached
to the magnetic beads, 50µl pre-heated Laemmli or NuPAGE LDS sample buffer (95) were added, the
elution fraction was analyzed by immunoblotting or mass spectrometry.
3.2.3.4 Co-immunoprecipitation
Cell lysates were prepared as described above (see 3.2.3.1). After pelleting the nuclei, the lysate was
transferred into a new tube, 1.5µl of α-GPF antibody (Roche) were added, and the sample was incubated
overnight at 4. Afterwards, 15 µl protein A/G beads were added, the sample was incubated for 1 h at
4. The beads were pelleted (250 g, 3 min, 4) and washed three times with 1 ml lysis buffer. The
proteins were eluted by adding 50 µl Laemmli-buffer (1x) and incubating the sample for 10 min at 90.
3.2.3.5 Subcellular fractionation by Balch homogenization
Ramos and DT40 cells were mechanically disrupted by shearing forces and subsequently fractionated on
a sucrose gradient based on the protocol described in Bethani et al. [12]. 3·108 cells were pelleted (300 g,
6 min) and washed once with homogenization buffer. They were resuspended in 1 ml homogenization
buffer and disrupted by being passed 30 times through a Balch homogenizer. The used Balch homogenizer
consisted of a metal block that contained two connected openings. A very exactly fitting metal sphere was
placed in the conneting conduit. The liquid containing the cells was slowly passed through the conduit
by using two syringes connected to the openings. Passing the small space between the sphere and the
conduit walls exerts strong shearing forces to the cells. After disruption, the nuclei were sedimented
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(2000 g, 15 min, 4). The postnuclear supernatant (PNS) was adjusted to a volume of 3 ml and a sucrose
concentration of 55% and overlaid with 2 ml of 45%, 3 ml of 35%, and 3 ml of 25% sucrose. Upon
centrifugation for 5 hours at 217,000 g, fractions were collected and analyzed by immunoblotting.
3.2.3.6 Subcellular fractionation by cavitation
Ramos B cells were disrupted by nitrogen cavitation. The cytosolic and the membranous fraction were
separated as described in Araujo et al., [33]. 5·107 cells were pelleted (300 g, 6 min), washed once with
homogenization buffer, and resuspended in 2 ml homogenization buffer. The liquid containing the cells
was transferred into a cell disruption vessel which was connected to a nitrogen bottle. The pressure in the
vessel was increased to 8 bar for 3 min. Afterwards, the pressure was abruptly released to disrupt the cells
by cavitation. The sample was centrifuged to pellet the nuclei (2000 g, 15 min, 4) and the postnuclear
supernatant (PNS) was subjected to ultracentrifugation (100,000 g, 1h, 4). The supernatant containing
the cytosolic proteins was removed and subjected to another centrifugation (100,000 g, 1h, 4) to remove
remaining membranous components. The supernatant of the second centrifugation was considered as
cytosolic fraction. The membrane pellet of the first centrifugation was resuspended in PBS containing
0.3% Triton X-100 and regarded as membranous fraction. Cytosolic and membranous fraction were
analyzed by immunoblotting.
3.2.3.7 SDS-PAGE
To separate proteins according to their size under denaturing conditions, SDS-polyacrylamide gel elec-
trophoresis (PAGE) was used, based on a protocol originally described by U. Laemmli [98]. In this
discontinuous gel system, the proteins were first concentrated in a stacking gel, followed by separation in
a resolving gel. The acrylamide concentrations for stacking gel (5% acrylamide) and resolving gel (10%
acrylamide) were chosen according to the size of the proteins of interest (as described in Chrambach and
Rodbard [25]). The solutions were prepared as indicated above (see 3.1.5). Gel casting and electrophore-
sis were performed with the Mini PROTEAN system (Biorad) or with the electrophoresis system Hoefer
SE600 (Amersham). Before application on the gel, all samples were mixed with Laemmli buffer (5x,
final concentration 1x) and incubated at 90 for 5 min. Electrophoresis was performed in SDS-PAGE
running buffer, at a current of 15 mA to 25 mA for Mini PROTEAN gels or 10 mA for Hoefer SE600
gels. To standardize the observed protein sizes, a prestained protein marker (NEB) was used. After
electrophoresis, the gel was subjected either to immunoblotting or Coomassie staining.
3.2.3.8 Coomassie staining
Recombinantly expressed proteins were visualized in polyacrylamide gels by staining with the dye Coomassie
Brilliant Blue R-250 following a procedure described in De St. Groth et al. [57]. For the detection of
proteins, the acrylamide gel was incubated for 1 h in Coomassie staining solution on a shaker followed by
overnight incubation in H2O to destain the gel matrix.
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3.2.3.9 Immunoblotting
For the specific detection of a protein species, the proteins separated on a acrylamide gel were transferred
to a nitrocellulose membrane as originally described in Towbin et al. [182]. Subsequently, proteins were
visualized via Horseradish peroxidase (HRP)-coupled antibodies. The transfer from gel to membrane
occurred in a semi-dry blotting apparatus. Gel and membrane were placed between two layers of What-
man paper soaked in blotting buffer. For protein transfer, a current of 200 mA (Mini PROTEAN gel)
or 240 mA (Hoefer SE600 gel) was applied for 1 h. Afterwards, the membrane was incubated in blocking
solution for 1 h, followed by overnight incubation in primary antibody solution containing the antibody
against the protein of interest (primary antibody). The primary antibody was diluted 1:1000 (α-Blnk,
α-clathrin heavy chain, α-GFP, α-GM130, α-Grb2, α-LAMP1, ,α-Lyn α-α-tubulin, α-VAMP7), 1:2000
(α-Akt, α-HA), 1:750 (α-CIN85), or 1:500 (α-Rab5). After three times washing in TBS-T (20 min each),
the membrane was incubated for 1 h in TBS-T containing an HRP-conjugated antibody against the pri-
mary antibody (secondary antibody, dilution 1:10,000 in TBS-T). The membrane was washed three to
five times for 20 min in TBS-T, the HRP-signal was visualized by adding ECL solution and recording
the emitted chemiluminescence using the Chemi Lux Gel Imager (Intas). To reprobe the membrane
with another primary antibody, the HRP-signal was erased by incubation with sodium azide (0.1% in
TBS-T) for 1 h. After 1 h wahing in TBS-T, the next primary antibody was applied. The following
chemiluminescence detection process remained unaltered.
3.2.3.10 Recombinant protein production in E. coli
The production of N-terminally His6-tagged recombinant proteins was performed as described in Engelke
et al. [40]. The pET16b plasmid carrying the desired insert was transformed into E. coli BL21. A E.
coli culture in 50 ml LB medium containing Ampicillin was grown to a optical density (600 nm) of 0.6
before the protein expression was induced by adding 1 mM IPTG. 4 h after induction the bacteria were
pelleted (4000 g, 10 min). The pellet was resuspended in 1 ml LEW buffer and homogenized by three
times 30 s sonification. Triton X-100 was added to a final concentration of 0.25% before 30 min lysis on
ice. The lysate was cleared of debris by centrifugation (16,000 g, 20 min, 4) and loaded on a Protino
Ni-IDA column (Macherey-Nagel), equilibrated in LEW Buffer. After four times washing with LEW
buffer containing 20 mM Imidazol, the His6-tagged proteins were eluted by application of 1 ml Elution
buffer (1x) (Macherey-Nagel). For liposome flotation experiments, the sample was dialyzed overnight
against LEW buffer to reduce the imidazole concentration.
3.2.4 Optical methods
3.2.4.1 Confocal microscopy
The subcellular localization of proteins tagged with GFP-variants was observed via confocal laser scan-
ning microscopy as decribed in Lösing et al. [104]. For this procedure, 1·106 cells were pelleted by
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centrifugation (400 g, 3 min), washed twice with 1 ml Krebs-Ringer solution (1 mM CaCl2) and finally
resuspended in 800 µl Krebs-Ringer solution (1 mM CaCl2). Each well of the microscope chamber was
filled with 400µl of the sample. The image acquisition of images began after a resting time of 30 min




The expression of transduced DNA was checked by the observing the presence of the Citrine tag harbored
in the chimeric proteins. 2·105-1·106 cells were pelleted (300 g, 4 min), washed once in PBS, and resus-
pended in 400 µl PBS for Flow cytometry. The Citrine fluorescence was recorded in the FITC channel
(excitation 488 nm, filters 505 LP, 530/30) of the instrument.
Calcium ion influx measurement
Changes of the intracellular Ca2+ concentration upon B cell stimulation were quantified by flow cytome-
try as described in Stork et al. [169]. For this purpose, INDO-1, a Ca2+-sensitive fluoresent dye was used.
It displays a fluorescence emission maximum at 475 nm in its free from and at 400 nm in its Ca2+-bound
form. 1-1.5·106 DT40 cells were pelleted (300 g, 4 min) and resuspended in 700 µl RPMI-1640 medium
(5% FCS). After addition of 2.1µl pluronic F-127 (5%) and 0.7µl INDO-1 AM (Life technologies), the
cells were incubated at 30 for 25 min. 800 µl RPMI-1640 medium (10% FCS) were added, followed by
an incubation of 10 min at 37. The cells were washed three times with Krebs-Ringer solution (1 mM
CaCl2) and finally resuspended in 600µl Krebs-Ringer solution (1 mM CaCl2). A following incubation
for 20 min at 25 ensured the resting status of the cells and a stable baseline for the fluorescence signals.
Afterwards, the fluorescence signals for INDO-1 violet (excitation 325-355 nm, filter 405/20) and blue
(excitation 325-355 nm, filters 450 LP, 530/30) were recorded for 30 s. The ratio of these signals was
taken as parameter for the intracellular Ca2+ concentration. After the baseline acquisition, the cells were
stimulated with an α-IgM antibody (M4) and the fluorescence signal was recorded for 210 s. The analysis




4.1 CIN85 reduces the threshold for BCR recruitment of SLP65.
Our group has previously shown that the interaction of SLP65 with the adaptor protein CIN85 is cru-
cial for SLP65-plasma membrane recruitment as well as BCR-triggered downstream signaling events like
Ca2+ influx. [121]. To confirm this observation, I transduced slp65−/− DT40 B cells with SLP65-wt and
the CIN85 binding deficient variant SLP65-M2,3 (CIN85-binding Motifs 2 and 3 inactivated by R-to-A
exchange, Figure 4.1 A). I analyzed the Ca2+ influx upon BCR stimulation by flow cytometry. As shown
in Figure 4.1 B, the Ca2+ influx mediated by SLP65-M2,3 was markedly reduced compared to SLP65-wt.
The magnitude of this effect was dependent on the concentration of α-IgM antibody used for stimulation.
At high antibody concentrations (2µg/ml, lower panel), the difference between SLP65-wt and the M2,3
variant was relatively minute, while it increased with decreasing antibody concentrations (0-2µg/ml, up-
per panel). This suggests that the SLP65-CIN85 interaction reduces the threshold of a B cell to respond
to BCR ligation. Additionally, the BCR-stimulation induced plasma membrane recruitment of SLP65-
M2,3 was impaired compared to SLP65-wt. (Figure 4.1 C).
4.2 A fraction of CIN85 and SLP65 is membrane associated in resting B
cells.
Having confirmed the influence of CIN85 on the BCR signaling pathway, I addressed the mechanism by
which CIN85 binding supports SLP65 function. The SLP65-recruitment process to the BCR consists of
distinct steps, namely SLP65-membrane association in resting cells, followed by SLP65-translocation to
the plasma membrane and recruitment to the BCR upon activation. Like the SLP65-N-terminus, the
CIN85-CC has been implicated to mediate membrane association of proteins [40, 200]. To test if CIN85
may serve as a membrane anchor for SLP65 in resting B cells, I performed subcellular fractionation
experiments. To visualize the membrane-bound pool of CIN85 and SLP65, I established a detergent-
free mechanical method to disrupt the B cells as schematically shown in Figure 4.2 A. The cells were
mechanically disrupted by being passed through a Balch homogenizer, a device that homogenizes cells
by shearing them between two metal surfaces. Subsequently, the postnuclear supernatant (PNS) was
subjected to ultracentrifugation on a sucrose step gradient, separating membrane fractions including
membrane-associated proteins from the soluble cytosolic fraction. I tested the success of the subcellular
fractionation by the detection of marker proteins for different organelles and the cytosol.
I analyzed fractionated Ramos B cells by immunoblotting with the marker proteins shown in Figure 4.2 B.
The kinase Akt and Grb2 served as cytosolic markers. They were not present in the membrane fractions
(M1 and M2) but only in the bottommost fractions (M3 + Cyt, lanes 11-13) which contained the cytosol.
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Fig. 4.1: CIN85 binding enhances BCR-induced Ca2+ influx and SLP65-membrane recruitment.
Slp65−/− DT40 cells were transduced with Citrine-tagged SLP65-wt or SLP65-M2,3 (schematically shown
in A). The Ca2+ influx in Citrine positive cells upon stimulation with 0.2 µg/ml or 2µg/ml α-IgM was
monitored by flow cytometry (B). The SLP65-membrane recruitment upon stimulation with 2µg/ml
α-IgM was observed by confocal microscopy (C).
A plasma membrane-associated protein, the Src-kinase Lyn, was present in all fractions with the excep-
tion of the cytosolic ones and was especially enriched in the membrane-containing fractions M1 (lanes
4 and 5) and M2 (lanes 8-9). GM130 as a maker for the low density Golgi-compartments was localized
completely to the uppermost membrane fraction M1 (lanes 4 and 5), while the early endosome marker
Rab5 was found in M1 (lanes 4 and 5), M2 (lanes 8 and 9) as well as in the cytosolic fractions (M11-13).
SLP65 and CIN85 were present in M2 (lanes 8 and 9) and the cytosolic fractions (lanes 11-13). This
indicated the existence of different pools of SLP65 and CIN85 in resting B cells, one membrane-bound
and the other cytosolic.
I carried out further studies of the subcellular localization of SLP65 and CIN85 in DT40 B cells because
slp65−/− DT40 cells could be reconstituted with different SLP65 variants without the background of
endogenous SLP65. This allowed the assessment of the influence of SLP65-regions on the overall SLP65-
localization. Like in Ramos cells, CIN85 and SLP65-wt were distributed between membrane (lanes 7 and
8) and cytosolic fractions (lanes 11-13) in DT40 cells (Figure 4.3 A, two upper panels). The majority
of both proteins resided in the cytosolic fractions, confirming microscopic images that show a mostly
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Fig. 4.2: SLP65 and CIN85 reside in cytosolic and membranous fractions. Ramos B cells were mechani-
cally disrupted using a Balch homogenizer (see 3.2.3.5) and fractionated on a sucrose gradient (A). The
fractions were collected from top (1) to bottom (13) and analyzed by immunoblotting for Akt, Grb2,
Lyn, GM130, Rab5, CIN85, and SLP65 (B).
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cytosolic localization of SLP65 [40]. Next, DT40 cells expressing the SLP65-∆N variant, which is devoid
of the SLP65 N-terminus, were analyzed. These cells lacked the membrane-bound pool of SLP65 (Fig-
ure 4.3, third panel), consistent with the observation that the SLP65 N-terminus is per se a membrane
anchor [40]. The localization of CIN85 remained unaltered in these cells (Figure 4.3, forth panel). The
SLP65-M2,3 variant, which does not bind to CIN85, showed a reduced membrane-bound pool compared
to SLP65-wt (Figure 4.3 B, third panel). This suggested that CIN85 supports or enhances the SLP65
N-terminus-mediated membrane association. I determined the presence of SLP65-wt in the membrane
fractions (Figure 4.3, first panel, lanes 7 and 8) and Akt exclusively in the cytosolic fractions (Figure 4.3
B, first panel, lanes 11-13) to control the success of the subcellular fractionation.
Fig. 4.3: The SLP65 variants ∆N and M2,3 show reduced membrane association compared to SLP65-wt.
Slp65−/− DT40 cells reconstituted with SLP65-wt or SLP65-∆N were mechanically disrupted using a
Balch homogenizer (see 3.2.3.5) and fractionated on a sucrose gradient. The fractions were collected from
top (1) to bottom (13) and analyzed by immunoblotting for SLP65 and CIN85 (A). Slp65−/− DT40 cells
reconstituted with SLP65-wt or SLP65-M2,3 were mechanically disrupted using a Balch homogenizer (see
3.2.3.5) and fractionated on a sucrose gradient. The fractions were collected from top (1) to bottom (13)
and analyzed by immunoblotting for SLP65 and Akt (B).
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To assess a possible influence of the mechanical disruption method on these results, I also performed dis-
ruption by nitrogen cavitation as schematically shown in Figure 4.4 A. The cells were filled with nitrogen
at a pressure of 10 bar. By abrupt decompression, resulting in very fast extension of the gas within the
cells, the plasma membrane and potentially also the organelles were disrupted. The nucleus should stay
intact to avoid a high DNA concentration in the PNS which complicates sample handling. The PNS
was separated into two fractions by ultracentrifugation - the pellet containing membrane proteins and
the supernatant containing cytosolic proteins. I analyzed the distribution of SLP65 and CIN85, as well
as membrane and cytosolic markers between the two fractions (Figure 4.4 B). As expected, the integral
membrane protein LAMP1 was only present in the membrane fraction, while the cytosolic proteins Akt
and α-tubulin were concentrated in the cytosolic fraction. For SLP65 and CIN85, the signals in cytosolic
and membrane fraction had a similar intensity. This confirmed the existence of a membrane-bound and
a cytosolic pool of these two proteins in resting B cells.
Fig. 4.4: SLP65 and CIN85 reside in the cytosolic and the membranous fraction. Ramos B cells were
mechanically disrupted by cavitation in a cell disruption vessel (see 3.2.3.6) (A). Cytosol and membranes
were separated by ultracentrifugation. The two fractions were analyzed by immunoblotting for LAMP1,
α-tubulin, Akt, SLP65, and CIN85 (B).
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4.3 VAMP7+ vesicles display lysosomal characteristics but no detectable as-
sociation with CIN85 and SLP65.
The existence of a membrane-bound pool of SLP65 has also been shown in a recent publication of our
group. We demonstrated that SLP65 associates to specific intracellular vesicles positive for the Solu-
ble NSF attachment protein receptor (SNARE) VAMP7 and for ATP [40]. To get more insight into
the general composition of these vesicles and especially the role that CIN85 might play for targeting or
anchoring SLP65 to vesicular membranes, I attempted to purify these vesicles. I disrupted DT40 cells
expressing Cerulean-tagged VAMP7 mechanically and isolated VAMP7+ vesicles by magnetic α-GFP-
beads as depicted in Figure 4.5 A. Compared to cells expressing eGFP, the eluate from Cerulean-VAMP7
cells contained large amounts of VAMP7 (Figure 4.5 B, upper panel), and showed an enrichment for
the vesicular coat protein clathrin (middle panel) and CIN85 (lower panel). The whole proteome of the
isolated vesicles was determined by SILAC-based mass spectrometry, yielding a list of 358 enriched pro-
teins in VAMP7+ vesicles (Appendix 7.1). The majority of the identified proteins are known to exhibit
Golgi apparatus (46 proteins), endosomal (45 proteins), lysosomal (63 proteins) or plasma membrane
(82 proteins) localization or are implicated in vesicular transport (34 proteins). This is consistent with
the previously described lysosomal and endosomal localization of VAMP7 (reviewed in [23]). However,
SLP65 and CIN85 were not present in this vesicular proteome, suggesting either a weak association or
a low abundance of SLP65 in the entire pool of VAMP7+ vesicles. To analyze the VAMP7+ SLP65+
vesicles in detail, it will be necessary to identify further markers specific for these compartments.
4.4 Plasma membrane anchoring of SLP65 cannot substitute for the inter-
action with CIN85
If CIN85 served as a membrane anchor for SLP65, it should be possible to bypass the SLP65-CIN85 inter-
action by equipping SLP65 with a plasma membrane binding domain. To test this hypothesis, I created
chimeric proteins, consisting of a membrane-targeting domain and SLP65, and tested their dependence
on CIN85 binding. One chimeric protein contained the PLC-δ PH domain, a general plasma membrane-
anchoring domain. The other chimeric protein encompassed the tandem SH2 (tSH2) domains of Syk, a
specific BCR targeting device. It has been shown before that both domains, the Syk tSH2 domains and a
plasma membrane-anchoring domain, can replace the SLP65-N-terminus [67]. For this reason, I deleted
the SLP65 N-terminus (aa 1-45) in the chimeric proteins. This ensured that the membrane association of
the chimeric proteins depended only on the non-SLP65 domain because it abolished the possibly inter-
fering membrane targeting function of the SLP65-N-terminus. The SLP65 N-terminus might otherwise
confer some specificity as its membrane binding capacity depends on membrane curvature [136].
On its own, the SLP65 variant lacking the N-terminus (SLP65-∆N) shows neither specific intracellular
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Fig. 4.5: VAMP7+ vesicles show an enrichment of the vesicular coat protein clathrin and CIN85. DT40
cells expressing either Cerulean-tagged VAMP7 or soluble eGFP were mechanically disrupted using a
Balch homogenizer (see 3.2.3.5). Cerulean- or eGFP-containing components were enriched using affinity
purification with an α-GFP antibody coupled to magnetic beads (A). The eluates derived from cells
expressing Cerulean-tagged VAMP7 (left) or soluble eGFP (right) were analyzed by immunoblotting for
VAMP7, the clathrin heavy chain (hc) and CIN85 (B).
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localization in resting B cells nor plasma membrane recruitment or Ca2+ influx upon BCR stimulation
([87, 40], and Figure 4.6).
Fig. 4.6: The SLP65 N-terminus is crucial for BCR-induced Ca2+ influx. Slp65−/− DT40 cells were
transduced with Citrine-tagged SLP65-wt or SLP65-∆N (46-456) (schematically shown in A). The Ca2+
influx in Citrine positive cells upon stimulation with 0.2µg/ml α-IgM was monitored by flow cytometry
(B).
Slp65−/− DT40 cells were transduced with chimeric constructs that harbored SLP65 either capable
(SLP65-∆N) or incapable (SLP65-∆N-M2,3) of CIN85 binding (shown schematically in Figure 4.7 A). I
confirmed the plasma membrane targeting function of the PLC-δ PH domain by confocal microscopy in
resting cells (Figure 4.7 C) and analyzed the Ca2+ influx upon BCR stimulation (Figure 4.7 B). For the
PLC-δ-PH-SLP65 construct, CIN85 binding had an influence on Ca2+ signaling because the SLP65-M2,3
variant showed a strongly diminished Ca2+ influx (Figure 4.7 B). In contrast, there was no difference in
Ca2+ influx between SLP65-∆N and SLP65-∆N-M2,3 for the Syk-tSH2-SLP65 construct. This suggests
that CIN85 binding is dispensable for a SLP65-construct that is directly targeted to the BCR while it is
still needed for a construct residing unspecifically at the plasma membrane. These results implicate that
CIN85 is involved in the process of BCR targeting of SLP65.
4.5 The CIN85-CC supports SLP65 function.
Knowing from the last experiment that the function of CIN85 is not, or not exclusively, unspecific mem-
brane anchoring of SLP65, I wanted to determine which domain of CIN85 contributes to BCR targeting
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Fig. 4.7: SLP65 equipped with a plasma membrane anchor is still dependent on CIN85 binding. Slp65−/−
DT40 cells were transduced with the Citrine-tagged chimeric proteins depicted in (A). The shown SLP65-
∆N variants were fused either to the PH domain of PLC-δ (black and red line) or to the tSH2 domains
of Syk (blue and green line). The Ca2+ influx in transduced Citrine positive cells upon stimulation with
0.2 µg/ml α-IgM was monitored by flow cytometry (B). The intracellular localization of the chimeric
PLC-δ-PH-SLP65-∆N protein in resting cells was observed by confocal microscopy (C).
of SLP65. The SLP65-CIN85 interaction is mediated by the CIN85 SH3 domains [189, 121]. The ef-
fector function could reside in the SH3 domains, in the proceeding proline rich region (PRR), or in the
C-terminal CC of CIN85. So I replaced the SLP65 N-terminus with the different CIN85 domains to
investigate if the CIN85 domains can substitute the function of the SLP65 N-terminus for BCR recruit-
ment. Furthermore, I used SLP65 variants either capable (SLP65-∆N) or incapable (SLP65-∆N-M2,3)
of CIN85 binding to see if the chimeric proteins still depend on binding of full-length CIN85.
Slp65−/− DT40 cells were reconstituted with the CIN85-SLP65 chimeric protein depicted in Figure 4.8
A. The construct where the CIN85 SH3 domains (aa 1-328) substituted for the SLP65 N-terminus showed
unspecific cytosolic localization in resting cells, no plasma membrane recruitment upon BCR stimulation
(Figure 4.8 C, upper panel) and could not induce Ca2+ influx (Figure 4.8 B). In contrast, the construct
where the C-terminal half of CIN85 (PRR and CC, aa 329-665) substituted for the SLP65 N-terminus
resided in dot-like structures in resting cells (Figure 4.8 C, middle panel), comparable to the localization
we have previously described for SLP65-wt [40]. The chimeric protein was recruited to the plasma mem-
brane after BCR stimulation and enabled Ca2+ influx to the same extent as SLP65-wt (Figure 4.8 B).
Abolishing CIN85 binding by introduction of the SLP65-M2,3 variant into this chimeric protein did not
alter its localization (Figure 4.8 C, third panel) or diminish its signaling capacity.
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Fig. 4.8: The C-terminal part of CIN85 substitutes the SLP65 N-terminus. Slp65−/− DT40 cells were
transduced with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). The shown SLP65-∆N
variants were fused either to the SH3 domains of CIN85 (red and blue line) or to the PRR and CC of CIN85
(green and violet line). The Ca2+ influx in transduced Citrine positive cells upon stimulation with 1µg/ml
α-IgM was monitored by flow cytometry (B). Intracellular localization and membrane recruitment of the
chimeric proteins 1 min after BCR stimulation (2 µg/ml α-IgM) were observed by confocal microscopy
(C). The expression levels of the chimeric proteins were compared by detection of the Citrine fluorescence
signal by flow cytometry (D). Cell lysates of cells producing SLP65-wt (lanes 1 and 2), SLP65-∆N (lanes
3 and 4), CIN85-SH3-SLP65-∆N (lanes 5-8), or CIN85-PRR/CC-SLP65-∆N (lanes 9-12) were subjected
to immunoblot analysis for SLP65 (E).
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Fig. 4.9: The CIN85-CC substitutes the SLP65 N-terminus. Slp65−/− DT40 cells were transduced with
SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). SLP65-∆N was fused either to the
PRR of CIN85 (red line) or to the CC of CIN85 (blue line). The Ca2+ influx in transduced Citrine
positive cells upon stimulation with 2µg/ml α-IgM was monitored by flow cytometry (B). Intracellular
localization and membrane recruitment of the chimeric proteins 1 min after BCR stimulation (2 µg/ml
α-IgM) were observed by confocal microscopy (C).
To specify the effector region of CIN85, I divided the C-terminal half of CIN85 into its two regions,
creating the chimeric proteins shown in Figure 4.9 A. These constructs were expressed in slp65−/− DT40
cells. The construct where the the CIN85-PRR (aa 329-599) substituted for the SLP65 N-terminus
was not capable of exhibiting any of the SLP65-wt functions (Figure 4.9 B and C). In contrast, the
construct where the CIN85-CC (aa 594-665) substituted the SLP65 N-terminus was functional with re-
gard to plasma membrane recruitment and Ca2+ mobilization. This chimeric protein was present in
dot-like-structures in resting cells and exhibited plasma membrane recruitment and Ca2+ influx upon
BCR stimulation (Figure 4.8 B and Figure 4.9 C, lower panel), comparable to SLP65-wt. By these ex-
periments, I allocated the effector function of CIN85 to the CC, namely the last 72 amino acids of the
protein. Abolishing CIN85 binding by introduction of the SLP65-M2,3 variant in the CIN85-PRR-SLP65-
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∆N and CIN85-CC-SLP65-∆N constructs (Figure 4.10 A), led to no change regarding Ca2+ signaling,
localization and membrane recruitment (Figure 4.10 B and C). This indicates that a covalent link to the
CIN85-CC supports the function of SLP65 making the SLP65 N-terminus and CIN85 binding dispensable.
Fig. 4.10: The CIN85-CC substitutes the SLP65 N-terminus and CIN85 binding. Slp65−/− DT40 cells
were transduced with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). The SLP65-
∆N-M2,3 variant was fused either to the PRR of CIN85 (red line) or to the CC of CIN85 (blue line).
The Ca2+ influx in transduced Citrine positive cells upon stimulation with 1 µg/ml α-IgM was monitored
by flow cytometry (B). Intracellular localization and membrane recruitment of the chimeric CIN85-CC-
SLP65-∆N-M2,3 protein 1 min after stimulation (2 µg/ml α-IgM) were observed by confocal microscopy
(C).
4.6 The CIN85-CC is an autonomous domain and can be assembled from its
two halves.
To investigate if a specific spatial arrangement of the CIN85-CC with regard to SLP65 is needed for the
CC function, I created chimeric proteins harboring the CC at different intramolecular positions. The
chimeric proteins shown above (Figure 4.9 and Figure 4.10) had the CC arranged N-terminally of SLP65-
∆N, so I created chimeric proteins with C-terminal CC (Figure 4.11 A) and monitored the Ca2+ influx
of slp65−/− DT40 cells reconstituted with these constructs (Figure 4.11 B). Like the constructs with
N-terminal CC, the constructs with C-terminal CC showed Ca2+ mobilization comparable to SLP65-wt.
This led to the conclusion that the CC most likely acts as an independent module, providing its function
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independently of its position within the entire chimeric protein.
Fig. 4.11: C-terminal as well as N-terminal fusion of CIN85-CC to SLP65 substitutes the SLP65 N-
terminus and CIN85 binding. Slp65−/− DT40 cells were transduced with SLP65-wt or the Citrine-tagged
chimeric proteins depicted in (A). The shown SLP65-∆N variants were N-terminally fused either to PRR
and CC of CIN85 (red and blue line) or only to the CC of CIN85 (green line). The Ca2+ influx in
transduced Citrine positive cells upon stimulation with 2 µg/ml α-IgM was monitored by flow cytometry
(B).
In the following step, I created chimeric proteins containing only parts of the CC to identify a minimal
amino acid sequence that contributed to SLP65 localization and function. I analyzed constructs harbor-
ing either the N-terminal (CN , aa 594-631) or the C-terminal half (CC , aa 632-665) of the CIN85-CC.
These constructs were not functional, regardless if the half CC was arranged N-terminally (Figure 4.12
A) or C-terminally (Figure 4.12 B) of SLP65-∆N. This led to the conclusion that the CIN85-CC has to
act as a whole entity.
To determine possible complementation of the two CC halves, I created a construct that contained one
half of the CC at the N-terminus, the other half at the C-terminus of SLP65-∆N-M2,3 (Figure 4.13 A).
In one orientation, CC at the N-terminus and CN at the C-terminus of SLP65, the protein was totally
functional with regard to Ca2+ mobilization and membrane recruitment (Figure 4.13 B and C), substi-
tuting SLP65-wt completely. In the other orientation, CN at the N-terminus and CC at the C-terminus
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Fig. 4.12: Only the entire CIN85-CC can substitute the SLP65 N-terminus. Slp65−/− DT40 cells were
transduced with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A) and (B). The SLP65-
∆N-M2,3 variant was fused either to the N-terminal (CN , aa 594-631, red line) or to the C-terminal
half of CIN85-CC (CC , aa 632-665), blue line). The partial CIN85-CC was placed N-terminally (A) or
C-terminally (B) of SLP65. The Ca2+ influx in transduced Citrine positive cells upon stimulation with
1 or 2µg/ml α-IgM was monitored by flow cytometry (A and B).
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of SLP65, the protein was not functional. This indicated that not only the presence of the two CC
halves but also their spatial orientation in respect to each other is crucial. The functional orientation
would enable the reconstitution of the CC, on the condition that the SLP65 part of the protein has the
ability to form a loop-like structure. This reconstitution would be impossible in the other orientation
because the order of the two CC halves would be wrong. The reconstitution of the CC seems to occur
only intramolecularly. When two chimeric CIN85-SLP65 proteins, each bearing one half of the CC, were
expressed simultaneously in slp65−/− DT40 cells, this did not enable Ca2+ mobilization (Figure 4.13 D).
These results suggest that the entire CC is needed to support SLP65 functionally, but its position within
the chimeric protein has no influence on its function.
4.7 The CIN85-CC and the SLP65 SH2 domain have distinct functions.
Fusion with the CIN85-CC could substitute for the SLP65 N-terminus as well as for CIN85 binding. The
third functionality of SLP65 that mediates BCR recruitment is its SH2 domain (see 2.4). To see if the
CIN85-SLP65 chimeric protein still needs a functional SLP65 SH2 domain, I introduced the amino acid
exchange R372L in the SH2 domain. This exchange has been reported to lead to loss of function of SLP65
[2]. I transduced a variant of CIN85-CC-SLP65-∆N containing the R372L exchange (Figure 4.14 A) in
slp65−/− DT40 cells. This construct did not induce Ca2+ influx upon BCR stimulation (Figure 4.14 B),
despite membrane recruitment could be observed to a certain extent (Figure 4.14 C). That implies that
the CIN85-CC cannot replace the function of the SLP65 SH2 domain.
4.8 The interactome of CIN85 is diverse, but the number of interaction part-
ners of the CIN85-CC is diminutive.
To find possible protein ligands of the CIN85-CC, I performed interactome studies based on mass spec-
trometry including SILAC. This labeling procedure by heavy amino acid isotopes allows a reduction of
the background by the simultaneous analysis of a heavy labeled sample and a light labeled control (see
3.2.3.2). The identified ligands of CIN85 in the human B cell line Ramos, stimulated for 5 min with
α-IgM-F(ab’)2, are listed in Table 4.1. The majority of the proteins in the CIN85 interactome have been
previously described to interact with CIN85. I confirmed the well-established interactions with SLP65,
CD2AP, c-Cbl and Cbl-b. I also found the known CIN85 interacting adaptor proteins Crk, SH3BP1 and
STAP1. Furthermore, I identified the Crk-related protein Crk-like as a CIN85 interactor for the first
time. The interactome contained seven subunits of the cell cycle regulating ubiquitin ligase Anaphase
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Fig. 4.13: The CIN85-CC is complemented by its two halves in cis. Slp65−/− DT40 cells were transduced
with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). For the first construct (red line),
SLP65-∆N-M2,3 was C-terminally fused to the first half of CIN85-CC (C1, aa 594-631) and N-terminally
fused to the second half of CIN85-CC (C2, aa 632-665). For the second construct (blue line), SLP65-∆N-
M2,3 was C-terminally fused to the second half of CIN85-CC (C2, aa 632-665) and N-terminally fused
to the first half of CIN85-CC (C1, aa 594-631). The Ca2+ influx in transduced Citrine positive cells
upon stimulation with 2µg/ml α-IgM was monitored by flow cytometry (B). Intracellular localization
and membrane recruitment of the chimeric proteins 1 min after BCR stimulation (2 µg/ml α-IgM) were
observed by confocal microscopy (C). Slp65−/− DT40 cells were transduced with the Citrine-tagged
chimeric proteins depicted in D. The SLP65-∆N-M2,3 variant was fused to the whole CIN85-CC (black
line) or to the second half of CIN85-CC (C2, aa 632-665), red line). Cells transduced with the later
construct were subsequently transduced with another Citrine-tagged chimeric protein, harboring SLP65-
∆N-M2,3 N-terminally fused to the first half of CIN85-CC (C1, aa 594-631). This resulted in cells
co-producing two chimeric proteins, each carrying half a CIN85-CC (blue line). The Ca2+ influx in




Fig. 4.14: CIN85-CC cannot substitute the function of the SLP65 SH2 domain. Slp65−/− DT40 cells were
transduced with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). CIN85-CC was fused
to SLP65-∆N-M2,3 (red line) or SLP65-∆N harboring the additional amino acid exchange L372R (RL,
blue line). The Ca2+ influx in transduced Citrine positive cells upon stimulation with 1 µg/ml α-IgM was
monitored by flow cytometry (B). Intracellular localization and membrane recruitment of the chimeric
protein CIN85-CC-SLP65-∆N L372R 1 min after BCR stimulation (2µg/ml α-IgM) were observed by
confocal microscopy (C).
promoting complex (APC/C), four of which are known CIN85 interaction partners. It contained ad-
ditionally the cell cycle regulator CDC21 homolog for which no CIN85 interaction has been described
yet. The remaining identified proteins were Cytoskeleton regulators (CapZ proteins, Anillin), GTPase-
activating proteins (ARHGAP17, ARAP1, ASAP1, ADAP2), PI3 kinases or phosphatases (p85, p110,
SHIP1), the membrane trafficking regulator MIRab13 and the motor protein myosin ID. Three proteins
of unknown function were identified as CIN85 interactors in this interactome, SHKBP1, CCDC88B and
rhotekin 2. Via literature research, I was able to assign the CIN85 binding domains for most interaction
partners. 17 of the identified 27 interaction partners are known to bind to the CIN85 SH3 domains.
They are therefore most likely not relevant in the context of the SLP65-CIN85 interaction because the
CIN85-SH3-SLP65 construct was not functional (Figure 4.8). The same is true for four other interactions
partners known to bind to the CIN85-PRR as the CIN85-PRR-SLP65 construct was also not functional
(Figure 4.9). The remaining six proteins are CD2AP, Crk-like protein, CDC21 homolog, ADAP2, myosin
ID and CCDC88B.
Crk-like protein is very likely to bind to CIN85-PRR due to its homology to Crk. CD2AP is known to
bind to CIN85-CC, but its knockout has no effect on Ca2+ influx in DT40 cells [18]. So it does not play
a crucial role in BCR signaling. For the four remaining proteins, ADAP2, CDC21 homolog, myosin ID
and CCDC88B, there is no evidence or indication for a membrane-anchoring or BCR targeting function,
even though this cannot be formally ruled out. I also determined the interactome of CIN85 in resting
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Ramos B cells which gave a list of interaction partners that did not differ from Table 4.1. The set of
interaction partners in resting and activated Ramos cells is almost identical, indicating that the interac-
tions of CIN85 are mediated by constitutive SH3-PRR and CC interactions which are not influenced by
the phosphorylation processes occurring after BCR stimulation.
Tab. 4.1: The interactome of CIN85 in the human B cell line Ramos. A plasmid coding for strep-
tagged CIN85 was introduced in Ramos cells by electroporation. Three clones were selected,
mixed to avoid clonal effects, and labeled by growing them in SILAC medium containing the
heavy isotope labeled amino acids lysine+4 and arginine+6. As control, wt Ramos cells were
grown in medium with light amino acids. The differently labeled cells were stimulated for 5 min
with α-IgM-F(ab’)2 and subjected to affinity purification by streptavidin-coated beads. The
light and heavy labeled samples were pooled in 1:1 ratio and subsequently analyzed by mass
spectrometry. The experiment was repeated 4 times. Proteins appearing at least 2 times at
a heavy-to-light ratio of 3 or higher were regarded as definitive interaction partners of CIN85.
The forth column of the table indicates the CIN85 region that has been described to interact
with this ligand in the literature. This can be either the SH3 domains (SH3), the proline rich
region (PRR) or the coiled coil (CC).
Protein Uniprot Function CIN85 domain
SLP65 Q8WV28 Adaptor protein [20, 189, 130, 119,
121], SH3
CD2AP Q9Y5K6 Adaptor protein 20, [48, 72], CC
Crk P46108 Adaptor protein [55, 189], PR
Crk-like protein P46109 Adaptor protein
SH3BP1 Q9Y3L3 Adaptor protein [20], SH3
STAP1 Q9ULZ2 Adaptor protein [20, 91], SH3
c-Cbl P22681 Adaptor protein, ubiquitin
E3 ligase
[20, 65, 16, 189,
130, 200, 166], SH3
Cbl-b Q13191 Adaptor protein, ubiquitin
E3 ligase
[20, 65, 16, 174, 59]
SH3
APC/C subunits 1, 3,





Cell cycle regulator For APC/C
4,5,6,8: [65], SH3
CDC21 homolog P33991 Cell cycle regulator
Anillin Q9NQW6 Cytoskeleton regulator [65], SH3
CapZ α-1 P52907 Cytoskeleton regulator [71, 72], PR
CapZ α-2 P47755 Cytoskeleton regulator [71], PR
CapZ β P47756 Cytoskeleton regulator [71], PR
ARHGAP17 Q68EM7 GTPase-activating protein [20, 65, 190], SH3
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Protein Uniprot Function CIN85 domain
ARAP1 Q96P48 GTPase-activating protein [20, 65, 199], SH3
ASAP1 Q9ULH1 GTPase-activating protein [20, 65, 125, 117,
91], SH3
ADAP2 Q9NPF8 GTPase-activating protein
MIRab13 Q8N3F8 Membrane trafficking
regulator
[20, 65], SH3
PI3K p110 α P42336 PI3 kinase [55]
PI3K p110 δ O00329 PI3 kinase [20], SH3
PI3K p85 α P27986 PI3 kinase [55, 17, 20],
SH3+PR
SHIP1 Q92835 PI3 phosphatase [20, 91], SH3
Myosin ID O94832 Motor protein
SHKBP1 Q8TBC3 unknown [20, 65, 43, 16],
SH3
CCDC88B A6NC98 unknown
Rhotekin 2 Q8IZC4 unknown [20], SH3
To investigate the extent of conservation of CIN85 interactions between species, I determined the inter-
actome in chicken DT40 cells (Table 4.2). There were interaction partners common between human and
chicken cells, namely SLP65, CD2AP, Crk, SH3BP1, c-Cbl, Cbl-b, CapZ proteins, ASAP1, MIRab13,
p110, p85 and rhotekin 2. All of them have been shown before to interact with CIN85 SH3 domains or
PRR (with the exception of CD2AP, mentioned above). This means that no conserved interactor of the
CIN85-CC that could play a role in BCR signaling was identified.
Furthermore, the chicken CIN85 interactome contained the proteins Endophilin A2, FBXO28, G2 and
S phase-expressed protein 1, Katanin p60 ATPase-containing subunit A1, SH3 domain-containing pro-
tein 19, RASAL2, ASAP2, TBC1 domain family member 10A, SIPA1, three Carboxy-terminal kinesin
proteins and CLEC17a. The only membrane protein amongst these is CLEC17a. For this protein, a
knock-out in DT40 cells shows no effect on BCR signaling (Master thesis S. Pirkuliyeva).
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Tab. 4.2: The interactome of CIN85 in the chicken B cell line DT40. A plasmid coding for strep-
tagged CIN85 was introduced in DT40 cells by electroporation. Three clones were selected,
mixed to avoid clonal effects, and labeled by growing them in SILAC medium containing the
heavy isotope labeled amino acids lysine+4 and arginine+6. As control, wt DT40 cells were
grown in medium with light amino acids. The differently labeled cells were stimulated for
5 min with α-IgM (M4) and subjected to affinity purification by streptavidin-coated beads. The
light and heavy labeled samples were pooled in 1:1 ratio and subsequently analyzed by mass
spectrometry. The experiment was repeated 2 times. Proteins appearing 2 times at a heavy-to-
light ratio of 3 or higher were regarded as definitive interaction partners of CIN85. The forth
column of the table indicates the CIN85 region that has been described to interact with this
ligand in the literature. This can be either the SH3 domains (SH3), the proline rich region
(PRR) or the coiled coil (CC).
Protein Uniprot Function CIN85 domain
SLP65 Q9YGC1 Adaptor protein [20, 189, 130, 119,
121], SH3
CD2AP E1BW77 Adaptor protein [48, 72], CC
Crk Q04929 Adaptor protein [55, 189], PR
Endophilin A2 Q8AXV0 Adaptor protein [131], PR
SH3BP1 F1NDY2 Adaptor protein [20], SH3
c-Cbl F1NXW5 Adaptor protein, ubiquitin
E3 ligase
[20, 65, 16, 189,
130, 200, 166], SH3
Cbl-b F1NL77 Adaptor protein, ubiquitin
E3 ligase
[20, 65, 16, 174, 59]
SH3
FBXO28 F1P2Q9 Part of ubiquitin E3 ligase
complex
G2 and S phase-
expressed protein 1
F1NIS1 Cell cycle regulator [20, 65], SH3
CapZ α-1 P13127 Cytoskeleton regulator [71, 72], PR
CapZ α-2 P28497 Cytoskeleton regulator [71], PR
CapZ β P14315 Cytoskeleton regulator [71], PR
Katanin p60 ATPase-
containing subunit A1
Q1HGK7 Cytoskeleton regulator [65], SH3
SH3 domain-
containing protein 19
F1N8H5 Cytoskeleton regulator [65], SH3
ARHGAP-17 E1C8J2 GTPase-activating protein [20, 65, 190], SH3
RASAL2 F1NW82 GTPase-activating protein [65], SH3
ASAP1 E1BTH6 GTPase-activating protein [20, 65, 125, 117,
91], SH3
ASAP2 F1NKX8 GTPase-activating protein [125], SH3
60
4 RESULTS




SIPA1 R4GHA6 GTPase-activating protein





Q5ZI55 Motor protein [65], SH3
Kinesin-like protein F1NBH9 Motor protein
Kinesin-like protein R4GGT8 Motor protein
PI3K p110 α O42391 PI3 kinase [55]
PI3K p85 β E1C2C5 PI3 kinase
CLEC17a H9L2G9 Transmembrane lectin
Rhotekin 2 F1NAV3 unknown [20], SH3
To address the question of CIN85-CC interaction partners more specifically I elucidated the interactome
of a strep-tagged CIN85-CC-SLP65-∆N chimeric protein in slp65−/− DT40 cells. The list of interaction
partners of CIN85-CC-SLP65-∆N in resting DT40 cells (Table 4.3) contains CIN85, CD2AP, Grb2 and
CapZ which are also found to interact with SLP65-wt in resting DT40 cells [121]. Of the remaining
four identified proteins, only FBXO28 is also found in the CIN85 interactome, indicating that this is an
interactor of the CIN85-CC and not of SLP65-∆N. As a part of a soluble E3 ubiquitin ligase complex,
there is no hint that FBXO28 contributes to membrane anchoring or BCR targeting.
Taken together, the interactome analyses did not indicate that CIN85-CC exhibits its effector func-
tion for SLP65 through interaction with a protein ligand.
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Tab. 4.3: The interactome of the chimeric protein CIN85 CC-SLP65-∆N in the chicken B cell line
DT40. A plasmid coding for strep-tagged CIN85-CC-SLP65-∆N was introduced in slp65−/−
DT40 cells by electroporation. Three clones were selected, mixed to avoid clonal effects, and
labeled by growing them in SILAC medium containing the heavy isotope labeled amino acids
lysine+4 and arginine+6. As control, wt DT40 cells were grown in medium with light amino
acids. The differently labeled cells were subjected to affinity purification by streptavidin-coated
beads. The light and heavy labeled samples were pooled in 1:1 ratio and subsequently analyzed
by mass spectrometry. The experiment was repeated 3 times. Proteins appearing at least 2
times at a heavy-to-light ratio of 3 or higher were regarded as definitive interaction partners
of the chimeric protein. The forth column of the table indicates if this interaction has been
described before for SLP65.
Protein Uniprot Function Reference
SLP65 Q9YGC1 Adaptor protein [121]
CD2AP E1BW77 Adaptor protein [121]
CIN85 F1NKX7 Adaptor protein [121]
Grb2 Q07883 Adaptor protein [121]
CapZ α-1 P13127 Cytoskeleton regulator [121]
CapZ β P14315 Cytoskeleton regulator [121]
FBXO28 F1P2Q9 Part of ubiquitin E3 ligase
complex
TRIM62 E1BX13 Part of ubiquitin E3 ligase
complex
HUS1 E1C8I4 Cell cycle regulator
Acyl-CoA thioesterase 8 E1BVK8 Metabolic regulator
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4.9 The CC mediates PA association, but this is not sufficient to support
SLP65 function.
Because no protein ligand for the CIN85-CC with an obvious link to BCR signaling could be identified, I
studied direct lipid binding of the CC. There are two reports stating that CIN85 binds to the intracellular
membrane lipid phosphatidic acid (PA) by its CC [200, 201]. This binding depends on the presence of
the basic amino acid residues K645, K646, R648 and R650 of CIN85 [201]. To confirm the PA binding
capacity of the CIN85-CC within the chimeric CIN85-SLP65 protein, I performed an affinity purification
with PA coated beads (Figure 4.15 A). While recombinant SLP65-wt and SLP65-∆N showed little or no
affinity to the beads, recombinant CIN85-CC-SLP65-∆N associated to them.
Fig. 4.15: The CIN85-CC associates with PA containing membranes. His6-tagged recombinant proteins of
SLP65-wt (wt), SLP65-∆N (dN) and the chimeric protein CIN85-CC-SLP65-∆N (CC-∆N, schematically
shown in A) were produced. The association of these proteins to PA coated beads was tested by affinity
purification (A). The binding of CIN85-CC-SLP65-∆N and SLP65-∆N to liposomes containing different
PA concentration was determined by a liposome flotation experiment (B). The recombinant proteins were
mixed with liposomes, followed by separation of liposomes and soluble fraction by ultracentrifugation.
Liposomal fractions (1 and 2 for CC-∆N, 7 and 8 for-∆N) and soluble fractions (3-6 for CC-∆N, 9-12
for-∆N) were collected and analyzed by immunoblotting for SLP65. The liposome flotation experiment
was carried out by Sona Pirkuliyeva (see [136] for experimental details).
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To address the lipid anchoring mode of the CIN85-CC in system more comparable to intracellular struc-
tures, I conducted liposome-protein interaction studies together with Sona Pirkuliyeva. We investigated
the binding of a recombinantly produced CIN85-CC-SLP65-∆N chimeric protein to liposomes containing
different concentrations of PA by a liposome flotation assay. Fractions containing liposomes (lanes 1-2,
and 7-8) and soluble proteins (lanes 3-6 and 9-12) were analyzed by immunoblotting (Figure 4.15 B). The
chimeric protein did not bind to liposomes lacking PA (upper panel). With increasing PA concentration,
the amount of liposome-bound protein increased. A concentration of 10% PA (lowest panel) was sufficient
to associate virtually the complete amount of protein to the liposomes. SLP65-∆N without the CIN85-
CC did not bind to liposomes (Figure 4.15 B, right part), independent of the PA concentration. Only at
a PA concentration of 10% there seems to be a weak association to the liposomes, probably dependent on
the positively charged His-tag of the recombinant protein. The lack of PA binding of SLP65-∆N suggests
that the observed PA binding is a function inherent to the CIN85-CC. To assess the effect of PA binding
in regard to SLP65 function in vivo, I transduced a SLP65-∆N construct containing the PA binding motif
of Raf1 (Figure 4.16 A) in slp65−/− DT40 cells. The PA binding motif of Raf1 has been shwon to direct
other proteins to PA-containing cellular compartments [81]. The chimeric Raf1-SLP65 protein was not
able to restore Ca2+ influx (Figure 4.16 B), indicating that PA binding is not sufficient to support SLP65
function.
Fig. 4.16: The PA binding motif of Raf is insufficient to substitute the SLP65 N-terminus. Slp65−/−
DT40 cells were transduced with the Citrine-tagged chimeric proteins depicted in (A). The shown SLP65-
∆N variants were fused either to the CIN85-CC (black line) or to the PA binding motif of Raf (aa 391-426,
red line). The Ca2+ influx in transduced Citrine positive cells upon stimulation with 2µg/ml α-IgM was
monitored by flow cytometry (B).
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4.10 The CIN85-CC forms a stable parallel trimer.
Due to the fact that the search for protein and lipid interaction partners of the CIN85-CC gave no hint on
a mechanism for SLP65 support, we investigated the structure of the CC. Multiangle laser light scattering
(Figure 4.17 A) and mass spectrometry (Figure 4.17 B) analyses with the recombinant CIN85-CC were
performed by Dr. Leo Wong and Dr. Stefan Becker in Prof. Griesinger’s department. From the results,
it was evident that the CIN85-CC forms a trimer. NMR spectroscopy studies by Dr. Leo Wong resulted
in the parallel trimer structure of the CC shown in Figure 4.18 A. This structure demonstrated that the
CIN85 region between amino acid 609 and 662 forms an continuous CC. The CIN85-CC trimer displayed
a high stability as denaturation occurred only at 85(Figure 4.18 B).
Fig. 4.17: The CIN85-CC forms a trimer. A His6-tagged recombinant protein of the CIN85-CC was
produced and isolated by affinity purification. After cleavage of the His6-tag, the protein was analyzed
by light scattering (A) and mass spectrometry (B). For the light scattering analysis, the protein was sub-
jected to size exclusion chromatography. The chromatogram displayed a single peak which corresponded
to a molecular mass of 26.11 kDa according to multiangle laser light scattering (MALLS) analysis. This
corresponds to a CIN85-CC trimer (calculated weight of 26.2 kDa). The CIN85-CC was also subjeted
to ESI mass spectrometry. The spectrum displayed three peaks, corresponding to CIN85-CC monomer,
dimer and trimer. The trimer peak showed the highest intensity. The slightly higher molecular weight
of the trimer (27.67 kDa) compared to MALLS analysis resulted from isotope labeling of the CC for sub-
sequent NMR analysis (calculated isotope labeled weight of 27.7 kDa). The experiments were performed
and analyzed by Dr. Leo Wong and Dr. Stefan Becker.
65
4 RESULTS
Fig. 4.18: The CIN85-CC trimer displays a high stability. The preliminary structure of the CIN85-CC
was calculated on the base of data obtained in several NMR spectroscopy experiments (A). The CIN85-
CC was found to form a parallel trimer consisting of three molecules with continuous α-helical structure
between amino acid 609 and 662. The stability of the CIN85-CC against heat-induced denaturation was
determined by circular dichroism spectroscopy (B). The trimer denaturated at a temperature of 85.
The experiments were performed and analyzed by Dr. Leo Wong.
4.11 An amino acid exchange in the hydrophobic interface of the CC disrupts
its oligomerization and function.
Based on these observations, I wondered if oligomerization is per se the crucial function that the CIN85-
CC provides to SLP65. To abolish oligomerization of the CIN85-CC, I introduced an amino acid exchange
in the hydrophobic interface of the CC, exchanging leucine 619 for lysine. Leucine 619 is involved in the
formation of the CIN85-CC trimer (Figure 4.19 A), thus I suspected that its exchange might lead to loss
of oligomerization. Indeed, exclusively the monomeric form of CIN85-CC L619K could be observed by
mass spectrometry (Figure 4.19 B). I obtained an identical result by co-immunoprecipitation of differ-
ently tagged forms of the chimeric CIN85-SLP65 protein (Figure 4.19 C). When I co-transfected cells
with HA-tagged CIN85-CC-wt SLP65-∆N and Citrine-tagged CIN85-CC-wt SLP65-∆N, it was possible
to co-precipitate the HA-tagged form with the Citrine-tagged form (lane 3), indicating oligomerization.
If one of the transfected proteins harbored the L619K exchange in the CC (lane 4), this co-precipitation
was not possible, suggesting a loss of oligomerization.
I fused the CIN85-CC L619K variant to SLP65-∆N-M2,3 (Figure 4.20 A), transduced the construct in
slp65−/− DT40 cells, and analyzed the Ca2+ influx in these cells upon α-IgM stimulation (Figure 4.20 B).
The Ca2+ influx mediated by the chimeric protein with L619K exchange was severely impaired compared
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Fig. 4.19: The exchange of leucine 619 for lysine prevents the oligomerization of the CIN85-CC. As seen
from the CIN85-CC structure, leucine 619 is involved in the formation of the hydrophobic interface of
the CC trimer (A). A His6-tagged recombinant protein of the CIN85-CC harboring L619K was produced
and analyzed by ESI mass spectrometry (B). The only identified species corresponds to a monomer of
CIN85-CC. The experiments were carried out by Dr. Leo Wong and Dr. Stefan Becker. Slp65−/−
DT40 cells were co-transduced with HA- and Citrine-tagged chimeric proteins of CIN85-CC and SLP65-
∆N-M2,3. The CIN85-CC of the Citrine-tagged proteins consisted either of CC-wt or CC L619K. The
Citrine-tagged proteins were immunoprecipitated using α-GFP antibody. Cell lysates (left part) and
immunoprecipitated fractions (right part) were analyzed by immunoblotting for GFP and HA (C).
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to the construct harboring the CIN85-CC-wt. Also its membrane recruitment was strongly impaired
(Figure 4.20 C). This implicated that the CIN85-CC L619K variant provided hardly any support for the
SLP65 function. In contrast, a CIN85-CC variant with the exchange of leucine 619 for alanine which
preserved the integrity of the hydrophobic interface showed only a slight decrease in Ca2+ signaling com-
pared to CIN85-CC-wt (Figure 4.20 B).
Fig. 4.20: Preventing CIN85-CC oligomerization abolishes its supporting function for SLP65. Slp65−/−
DT40 cells were transduced with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). The
SLP65-∆N-M2,3 variant was fused to CIN85-CC, either CC-wt (red line), CC L619K (blue line) or CC
L619A (green line). The Ca2+ influx in transduced Citrine positive cells upon stimulation with 0.2 or
1 µg/ml α-IgM was monitored by flow cytometry (B). Intracellular localization and membrane recruitment
of the chimeric CIN85-CC L619K SLP65-∆N-M2,3 protein 1 min after BCR stimulation (2 µg/ml α-IgM)
were observed by confocal microscopy (C).
I tested the PA binding ability of CIN85-CC L619K by a liposome flotation assay (Figure 4.21). The
CIN85-CC-L619K-SLP65-∆N protein (lanes 7-12) behaved in this assay like CIN85-CC-wt-SLP65-∆N
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protein (lanes 1-6), indicating that the L619K exchange does not abolish PA binding of the CIN85-CC.
So the loss of oligomerization, but not of the PA binding ability, correlated with a loss of function.
Fig. 4.21: CIN85-CC L619K associates with PA containing membranes. His6-tagged recombinant CIN85-
CC-wt-SLP65-∆N and CIN85-CC-L619K-SLP65-∆N proteins were produced. The binding of these pro-
teins to liposomes containing different PA concentration was determined by a liposome flotation exper-
iment. The recombinant proteins were mixed with liposomes, followed by separation of liposomes and
soluble fraction by ultracentrifugation. Liposomal fractions (1 and 2 for CC-wt, 7 and 8 for CC L619K)
and soluble fractions (3-6 for CC-wt, 9-12 for CC L619K) were collected and analyzed by immunoblot-
ting for SLP65. The liposome flotation experiment was carried out by Sona Pirkuliyeva (see [136] for
experimental details).
4.12 Other CC domains can replace the CIN85-CC to support SLP65.
If oligomerization was the main or exclusive mechanism of the CIN85-CC to support SLP65 function, it
should be possible to substitute the SLP65 N-terminus and CIN85 binding by fusion to other oligomer-
ization domains. First, I fused SLP65-∆N to the CC of the CIN85 homolog CD2AP (CD2AP aa 568-639,
Figure 4.22 A). The CIN85-CC and the CD2AP-CC display a high degree of similarity, harboring 38%
identical and another 32% similar amino acid residues. I transduced the CD2AP-CC-SLP65-∆N con-
struct in slp65−/− DT40 cells, the Ca2+ influx upon α-IgM stimulation was monitored. The construct
enabled a Ca2+ influx comparable to SLP65-wt (Figure 4.22 B). The deletion of the CIN85 binding sites in
the CD2AP-CC-SLP65-∆N construct, resulting in CD2AP-CC-SLP65-∆N-M2,3, impaired the Ca2+ in-
flux only slightly, indicating that CIN85 binding is dispensable for CD2AP-CC-SLP65-∆N. The chimeric
CD2AP-SLP65 protein was recruited to the plasma membrane upon BCR stimulation (Figure 4.22 C).
To investigate if there may be binding partners which could recruit the CD2AP-CC to the BCR, I stud-
ied the CD2AP interactome in the human B cell line Ramos by SILAC-based mass spectrometry. This
experiment resulted in the list of interaction partners given in Table 4.4. The interactome of CD2AP was
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Fig. 4.22: The CD2AP-CC substitutes the SLP65 N-terminus. Slp65−/− DT40 cells were transduced
with SLP65-wt or the Citrine-tagged chimeric proteins depicted in (A). The shown SLP65-∆N variants
were fused to the CD2AP-CC (red line and blue line). The Ca2+ influx in transduced Citrine positive
cells upon stimulation with 1 µg/ml α-IgM was monitored by flow cytometry (B). Intracellular localization
and membrane recruitment of the chimeric proteins 1 min after BCR stimulation (2 µg/ml α-IgM) were
observed by confocal microscopy (C).
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partially identical to the interactome of CIN85. Additionally, the heavy chain of the IgD-BCR, but not
the one of the IgM-BCR, was found to interact with CD2AP. There were no obvious candidate molecules
mediating membrane anchoring or IgM-BCR recruitment of the CD2AP-CC.
Tab. 4.4: The interactome of CD2AP in the human B cell line Ramos. A plasmid coding for
strep-tagged CD2AP was introduced in Ramos cells by electroporation. Three clones were se-
lected, mixed to avoid clonal effects, and labeled by growing them in SILAC medium containing
the heavy isotope labeled amino acids lysine+4 and arginine+6. As control, wt Ramos cells
were grown in medium with light amino acids. The differently labeled cells were stimulated
for 5 min by α-IgM-F(ab’)2 and subjected to affinity purification by streptavidin-coated beads.
The samples of strep-tagged CD2AP expressing and control cells were pooled in 1:1 ratio and
subsequently analyzed by mass spectrometry. The experiment was repeated 3 times. Proteins
appearing at least 2 times at a heavy-to-light ratio of 3 or higher were regarded as definitive
interaction partners of CD2AP. The forth column of the table indicates if this interaction has
been described before for CD2AP.
Protein Uniprot Function Reference
SLP65 Q8WV28 Adaptor protein [121]
CIN85 Q96B97 Adaptor protein [48, 181, 73]
SH3BP1 Q9Y3L3 Adaptor protein
STAP1 Q9ULZ2 Adaptor protein [73]
ALKBH2 Q6NS38 DNA repair protein
CapZ α-1 P52907 Cytoskeleton regulator [71, 180, 8]
CapZ α-2 P47755 Cytoskeleton regulator [180, 73]
CapZ β P47756 Cytoskeleton regulator [180, 8]
ARHGAP17 Q68EM7 GTPase-activating protein [190]
ARAP1 Q96P48 GTPase-activating protein [72]
MIRab13 Q8N3F8 Membrane trafficking
regulator
Ig δ chain C region P01880 Immunoglobulin chain
Rhotekin 2 Q8IZC4 unknown [72]
As for CIN85-CC, I considered direct lipid binding of the CD2AP-CC. In contrast to the basic CIN85-CC
(pI 9.06), the CD2AP-CC is rather acidic (pI 5.50, as calculated with ExPASy.org) which could influence
the electrostatic interactions with membrane lipids to a large extent. I studied the PA binding of CD2AP-
CC in vitro by affinity purification. In contrast to CIN85-CC-SLP65-∆N, CD2AP-CC-SLP65-∆N could
not be precipitated with PA coated beads (Figure 4.23). This indicated that the PA binding ability of
the CC domains might be mainly driven by electrostatic interactions. As CIN85-CC and CD2AP-CC
can support SLP65 to a similar extent, the PA interaction seems to be dispensable for the function that
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is exhibited by the CC domains towards SLP65.
Fig. 4.23: CIN85-CC, but not CD2AP-CC, associates with PA. His6-tagged recombinant CIN85-CC-
SLP65-∆N and CD2AP-CC-SLP65-∆N proteins were produced. The association of these proteins to PA
coated beads was tested by affinity purification. The protein input (left side) and the affinity-purified
protein amount (PA-AP, right side) were analyzed by immunoblotting for SLP65.
In the next step, I employed CC domains with different oligomerization states to see if the formation of
differently sized SLP65 complexes influenced SLP65 function. The CC of the Small Coiled Coil protein
(SCOC) normally forms a dimer, but it can be converted to a trimer or tetramer by the exchange of
two amino acids [10]. I fused the SCOC-CC-wt (aa 78-159) to SLP65-∆N (Figure 4.24 A), transduced
the construct in slp65−/− DT40 cells, and monitored the Ca2+ influx upon α-IgM stimulation. The
SCOC-CC enabled Ca2+ influx, although the level was slightly decreased compared to the CIN85-CC
(Figure 4.24 B). The introduction of the M2,3 variant in the SCOC-CC-SLP65 construct enhanced this
difference (Figure 4.24 B). Also compared to CD2AP-CC, the SCOC-CC enabled Ca2+ influx to a lesser
extent (Figure 4.25). Nevertheless, the SCOC-CC-SLP65-∆N construct was recruited to the plasma
membrane upon BCR stimulation (Figure 4.24 C).
In the following experiment, I fused variants of the SCOC-CC with different oligomerization states to
SLP65-∆N-M2,3 (Figure 4.26 A), transduced the constructs in slp65−/− DT40 cells, and monitored the
Ca2+ influx upon α-IgM stimulation. A higher oligomerization state of the SCOC-CC-SLP65-∆N-M2,3
fusion proteins resulted in stronger Ca2+ influx (Figure 4.26 B and C). This effect was specially pro-
nounced at stimulation with low α-IgM concentrations (Figure 4.26 B). These results indicate again that
the oligomerization state of CC-SLP65-∆N chimeric proteins has a crucial influence on their functionality.
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Fig. 4.24: The SCOC-CC substitutes the SLP65 N-terminus. Slp65−/− DT40 cells were transduced
with the Citrine-tagged chimeric proteins depicted in (A). The shown SLP65-∆N variants were fused to
CIN85-CC (black line) or to SCOC-CC (red line and blue line). The Ca2+ influx in transduced Citrine
positive cells upon stimulation with 2µg/ml α-IgM was monitored by flow cytometry (B). Intracellular
localization and membrane recruitment of the chimeric proteins 1 min after BCR stimulation (2 µg/ml
α-IgM) were observed by confocal microscopy (C).
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Fig. 4.25: CIN85, CD2AP and SCOC-CC support the SLP65 function to a different extent. Slp65−/−
DT40 cells were transduced with the Citrine-tagged chimeric proteins depicted in (A). SLP65-∆N-M2,3
was fused to CIN85-CC (black line), CD2AP-CC (red line) or SCOC-CC (blue line). The Ca2+ influx in
transduced Citrine positive cells upon stimulation with 2 µg/ml α-IgM was monitored by flow cytometry
(B).
Fig. 4.26: Higher oligomerization states of SCOC-CC enhance its supporting function for SLP65. The
oligomerization state of SCOC-CC was changed by the introduction of amino acid exchanges (according
to [10]). Slp65−/− DT40 cells were transduced with SLP65-wt or the Citrine-tagged chimeric proteins
depicted in (A). The SLP65-∆N-M2,3 variant was fused to SCOC-CC, either CC-wt (dimeric, red line),
CC E93V/K97L (trimeric, blue line), or CC N125L/N132V (tetrameric, green line). The Ca2+ influx
in transduced Citrine positive cells upon stimulation with 0.2 or 1µg/ml α-IgM was monitored by flow
cytometry (B and C).
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4.13 Oligomerization enables SLP76 to take part in the BCR signaling cas-
cade.
To see if the concept of oligomerization of adaptor proteins could be generalized, I performed experiments
with SLP76, the SLP65-homolog in T cells. Slp65−/− DT40 B cells reconstituted with SLP76-wt show
virtually no Ca2+ influx or SLP76-membrane recruitment upon BCR stimulation, so SLP76-wt is not
capable to substitute SLP65 in BCR signaling [196]. This might be due to the lack of oligomerization of
SLP76, as the protein does not contain CIN85 binding sites. When CIN85 binding sites are introduced
to SLP76, this modified SLP76 protein mediates Ca2+ influx in B cells [121], indicating that increased
oligomerization could enable SLP76 to function in B cells. To test the oligomerization hypothesis, I
equipped SLP76 which the CIN85-CC (Figure 4.27 A). The construct was transduced in slp65−/− DT40
cells, the Ca2+ influx upon BCR-stimulation was comparable to CIN85-CC-SLP65-∆N-M2,3 (Figure 4.27
B). A fraction of the chimeric CIN85-SLP76 protein was plasma membrane associated in unstimulated
cells. This plasma membrane localization seemed to be slightly enhanced upon BCR stimulation (Fig-
ure 4.27 C). To ensure that this gain of function is really induced by the oligomerization function of the
CIN85-CC, I used also the monomeric CC variant L619K. When fused to SLP76, CIN85-CC L619K failed
to enable Ca2+ influx (Figure 4.27 B). So oligomerization is a prerequisite for SLP76 to participate in
BCR signaling.
4.14 Oligomerization of SLP65 is sufficient to enable BCR recruitment and
Ca2+ signaling.
To test oligomerization devices other than CC domains, I fused SLP65-∆N to the two parts of the split
Venus protein. Split Venus is used for Bimolecular fluorescence complementation (BiFC) studies because
its two halves VN and VC link covalently when they are spatially close to each other. This occurs for
example when they are fused to two interacting proteins (Figure 4.28 A). I transduced the constructs
VN-SLP65-∆N and VC-SLP65-∆N (Figure 4.28 B) either individually or simultaneously in slp65−/−
DT40 cells. The successful fusion of the Venus parts VN and VC in simultaneously transduced cells was
confirmed by their Venus fluorescence (Figure 4.28 C). This indicated the formation of a covalent SLP65
dimer.
I monitored the α-IgM-induced Ca2+ influx in the co-transduced cells. This revealed that a VN-SLP65-
∆N-VC-SLP65-∆N dimer enabled Ca2+ influx and plasma membrane recruitment comparable to SLP65-
wt (Figure 4.29). The functionality of the protein was not impaired by the introduction of the M2,3
variant in both of the SLP65 parts (Figure 4.30). On the other hand, the function of the SH2 domain in
the SLP65 parts was still important because the inactivating amino acid exchange R372L in both SLP65
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Fig. 4.27: The CIN85-CC enables SLP76 to mediate BCR-induced Ca2+ influx. Slp65−/− DT40 cells
were transduced with the Citrine-tagged chimeric proteins depicted in (A). SLP65-∆N-M2,3 was fused
to CIN85-CC-wt (black line) or to CIN85-CC L619K (blue line). SLP76 was fused to CIN85-CC-wt
(red line) or to CIN85-CC L619K (green line).The Ca2+ influx in transduced Citrine positive cells upon
stimulation with 2µg/ml α-IgM was monitored by flow cytometry (B). Intracellular localization and
membrane recruitment of the chimeric protein CIN85-CC-wt-SLP76 1 min after BCR stimulation (2µg/ml
α-IgM) were observed by confocal microscopy (C).
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Fig. 4.28: A covalently linked SLP65-∆N dimer is obtained by fusion of a split Venus protein. The yellow
fluorescent protein (YFP) variant Venus can be reconstituted by its two parts VN (aa 1-173) and VC (aa
156-239). This fusion is enabled by spatial proximity of proteins linked to VN and VC (schematic in A,
graphic from Shyu et al. [165]). Slp65−/− DT40 cells were transduced with Citrine-tagged SLP65-wt or
SLP65-∆N fused to a part of Venus chimeric proteins, as depicted in (B). SLP65-∆N was fused to VN
(red line) or VC (blue line). Moreover, slp65−/− DT40 cells were co-transduced with VN-SLP65-∆N and
VC-SLP65-∆N (green line). The fluorescence of the transduced cells was monitored by flow cytometry
in the FITC channel (C).
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parts totally abolished the functionality of the SLP65-dimer (Figure 4.30). This result indicated that
SLP65 oligomerization can fully substitute the functions of SLP65 N-terminus and CIN85 binding. It
further suggested that the function of CIN85 in the BCR signaling pathway is the stabilization of large
SLP65 oligmers, presumably in cooperation with the membrane binding ability of the SLP65 N-terminus.
Fig. 4.29: Covalent linkage of two SLP65 molecules substitutes the SLP65 N-terminus. Slp65−/− DT40
cells were transduced with Citrine-tagged SLP65-wt or SLP65-∆N fused to a part of Venus chimeric
proteins, as depicted in (A). VN SLP65-∆N and VC SLP65-∆N were transduced individually (red and
blue line) or simultaneously (green line). The Ca2+ influx in transduced cells upon stimulation with
0.2 or 2µg/ml α-IgM was monitored by flow cytometry (B). For cells expressing VN-SLP65-∆N and
VC-SLP65-∆N simultaneously, intracellular localization and membrane recruitment 1 min after BCR
stimulation (2 µg/ml α-IgM) were observed by confocal microscopy (C).
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Fig. 4.30: CIN85 binding is dispensable for the covalently linked SLP65-∆N dimer. Slp65−/− DT40
cells were transduced with Citrine-tagged SLP65-wt or with one VN-SLP65-∆N and one VC-SLP65-∆N
construct simultaneously. Both SLP65-∆N parts of the proteins harbored either the wt form (red line),
the M2,3 variant (blue line) or the R372L variant (green line). The Ca2+ influx in transduced cells upon




5.1 CIN85-mediated oligomerization of SLP65
In this doctoral thesis, I investigated the influence of the adaptor protein CIN85 on BCR signaling. I
focussed on the interaction of CIN85 with the adaptor protein SLP65. This interaction is important for
efficient SLP65-membrane recruitment and Ca2+ signaling in DT40 cells (Figure 4.1 and [121]). To eluci-
date the mechanism by which CIN85 supports SLP65 function, I constructed chimeric proteins of SLP65
and membrane-anchoring domains and investigated if CIN85 binding is required for the function of these
chimeric proteins. The SLP65-CIN85 interaction could not be substituted by the PLC-δ PH domain,
a general plasma membrane anchor (Figure 4.7). Other chimeric proteins of SLP65 and membrane-
anchoring domains have been investigated on their need for CIN85 binding. SLP65-∆N was fused to
the plasma membrane-anchoring domain of TIRAP [18], to the Golgi apparatus-anchoring OSBP1 PH
domain [121] and to the vesicle anchoring amphiphysin N-BAR domain [136]. In consistence with my
results, it was found that all these domains can substitute for the SLP65 N-terminus, but all constructs
were still dependent on CIN85 binding for Ca2+ signaling. Thus, CIN85 seems to exhibit its function
on SLP65 regardless of the SLP65 localization which is determined by the extrinsic membrane-anchoring
domains or, for SLP65-wt, by the SLP65 N-terminus [40]. Because the extrinsic membrane-anchoring
domains confer specific and strong membrane anchoring, it is unlikely that CIN85 is important for the
association of SLP65 with membranes. On the other hand, I could show that CIN85 binding is dispens-
able for chimeric SLP65 proteins containing the BCR-anchoring Syk tandem SH2 domains (Figure 4.7).
This indicates that CIN85 is important for the recruitment process of membrane associated SLP65 to the
BCR rather than for subsequent anchoring of SLP65 to the activated BCR.
A similar phenomenon has been found for the adaptor function that SLP65 itself provides for PLC-γ2.
The PLC-γ2 recruitment to the BCR is dependent on its binding to SLP65. This need cannot be bypassed
by targeting PLC-γ2 unspecifically to the plasma membrane by fusion with the PLC-δ PH domain [149].
However, targeting PLC-γ2 specifically to lipid rafts and thus in proximity of the BCR via a 9-amino
acid membrane anchor of Lyn is sufficient to enable PLC-γ2 function without SLP65 binding. [149].
It is likely that the attachment of the membrane anchor of Lyn to SLP65 would make CIN85 binding
dispensable.
By the creation of CIN85-SLP65 chimeric proteins, I could attribute the supporting function of CIN85
to its CC domain (Figure 4.8, Figure 4.9 and Figure 4.10) because chimeric proteins of SLP65-∆N and
the CIN85-CC were not dependent on additional CIN85 binding (Figure 4.10). The CIN85-CC could be
located N- or C-terminally of SLP65 with the same outcome (Figure 4.11). It could even be reconstituted
from its two halves placed on the two ends of the chimeric protein (Figure 4.13). These observations in-
dicate that the CIN85-CC is an independent functional domain that supports SLP65 function regardless
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of its position and thereby probably without interactions with other parts of the fusion protein.
However, a protein ligand of the CIN85-CC that is known to influence BCR signaling could not be identi-
fied by mass spectrometry (Table 4.1 Table 4.2 and Table 4.3). The CIN85 interactome of human Ramos
B cells and chicken DT40 B cells overlapped to a large extent with the interactome that Büchse and
colleagues prepared from the mouse B cell line WEHI 231. [20]. Also their interactome gives no hint of
an interaction partner that could direct the CIN85-CC in proximity of the BCR. The direct interaction of
the CIN85-CC with PA, reported by Zhang and colleagues [200], could be confirmed by our experiments
(Figure 4.15) but seemed dispensable for the functional support of SLP65 (Figure 4.16, Figure 4.21, and
Figure 4.23).
The need of SLP65 oligomerization for its function could be demonstrated by the creation of chimeric
proteins with different oligomerization domains. The CN85-CC and the CD2AP-CC could substitute for
the SLP65 N-terminus and for CIN85 binding. However, this left the possibility that these two closely
related domains might bind to a ligand responsible for BCR recruitment, even though no such ligand
could be identified in my studies. The N-terminus of SLP65 could also be substituted by the SCOC-CC
which is not related to the CIN85-CC and the CD2AP-CC. By modifying the oligomerization state of
the SCOC-CC due to introduction of amino acid exchanges, I could observe that SLP65 functions the
better the higher it is oligomerized (Figure 4.26). As the SCOC-CC shows no relation to the CIN85-CC,
it can be presumed that their only common function is oligomerization.
The gradual differences in the ability of the CC domains to support SLP65 function (Figure 4.25) can
be explained by their different oligomerization states and their affinity for oligomerization. In cooper-
ation with C. Griesinger’s group, I could show that the CIN85-CC forms a very stable trimer. This
trimer formation seemed to be slightly impaired by the exchange of leucine 619 for alanine, resulting in a
slight decrease in Ca2+ influx (Figure 4.20). The exchange of leucine 619 for lysine abolished the trimer
formation completely (Figure 4.19) and led to almost complete inhibition of Ca2+ signaling mediated
by chimeric CIN85-SLP65 proteins (Figure 4.20). The CD2AP-CC forms presumably an oligomer very
similar to the CIN85-CC, due to their large degree of homology, resulting in a similar ability to support
SLP65 function (Figure 4.25). Also hetero-trimerization of CD2AP-CC and CIN85-CC is possible. In
contrast, the SCOC-CC-wt forms a dimer that might be less stable than the CIN85-CC and CD2AP-CC
oligomers. To support SLP65 function as efficiently as these two CC domains, it is necessary to introduce
amino acid exchanges in the SCOC-CC that result in a higher oligomerization state (trimer or tetramer).
The covalent dimerization of SLP65 by chimeric proteins with split Venus could substitute for the SLP65-
N terminus and for CIN85 binding (Figure 4.30). Two Venus molecules have been shown to associate
with low affinity [144, 116], so that also a SLP65 tetramer could be formed. This can explain why the
fusion to split Venus can support the SLP65 function to the same extent as fusion to the CC domains.
Taken together, the results suggest that SLP65 membrane recruitment crucially requires oligomerization.
Furthermore, they indicate that the SLP65 N-terminus and CIN85 might cooperate in the oligomerization
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of SLP65 because oligomerized chimeric SLP65 proteins were not dependent on both of them.
5.2 The formation of the SLP65-CIN85 complex
In the physiological situation, the oligomerization of SLP65 will occur by its interaction with CIN85. The
CIN85-CC forms a trimer, resulting in a CIN85 protein complex with nine SH3 domains which means
nine potential binding sites for SLP65 molecules. The CIN85 trimer could be very potent in forming large
protein complexes as it binds to several SLP65 molecules at the same time. However, native PAGE ex-
periments reveals exclusively the existence of a SLP65-containing 180 kDa complex [173]. This might be a
hint that the large complexes are very labile or require the presence of intact membranes. Their existence
might also mainly depend on the local concentration of the two interacting proteins. The equilibrium of
complex formation will always be shifted towards the loss of oligomerization by conventional purification
methods. The physiological size of the SLP65-CIN85 complexes remains to be elucidated. Nevertheless,
the physiological relevance of the SLP65-CIN85 interaction in vivo is proven by co-localization experi-
ments in living cells and the fact that the CIN85 binding deficient SLP65 variant M2,3 shows reduced
plasma membrane recruitment and Ca2+ signaling upon BCR stimulation [121].
The CIN85-mediated SLP65 oligomerization seems to require pre-concentration of SLP65 to be efficient.
The exclusively cytosolic SLP65 variant ∆N, which is still capable of CIN85 binding in vitro, is not func-
tional in regard to membrane recruitment and Ca2+ mobilization [40] and Figure 4.6). This indicates that
SLP65 oligomerization by CIN85 SH3 domain binding is not sufficient to enable the formation of large
SLP65-∆N complexes as it can be achieved by direct fusion of SLP65-∆N to the mentioned oligomer-
ization domains. The pre-concentration of SLP65 might have a major influence on the equilibrium of
the SLP65-CIN85 interaction. Interactions between SH3 domains and proline motifs have typically a
modest affinity in the low micromolar range [100, 82]. So a functional interaction might require high
avidity by high local concentrations of both binding partners. Low-affinity interactions that are largely
influenced by concentrations might provide a possibility to modify the composition of protein complexes
very rapidly, a feature especially important in signal transduction. Kowanetz and colleagues proposed a
rapid exchange of CIN85 interaction partners dependent on varying local concentrations at different time
points of EGFR internalization [91].
A high local concentration of SLP65, provided by N-terminus-mediated membrane association of SLP65
molecules, might be necessary to outcompete the various other binding partners of the CIN85 SH3 do-
mains. This promiscuity of CIN85 interactions is outlined by the CIN85 interactome (Table 4.1). The
competition of different proteins for CIN85 SH3 domain binding and its functional consequences have
already been described for c-Cbl. Ubiquitination and internalization of the EGFR are dependent on
CIN85-mediated c-Cbl-clustering [92]. The proteins Alix, Sprouty, Dab2 and SHKBP1 can compete with
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c-Cbl for CIN85 SH3 domain binding. Their expression reduces the effective clustering of c-Cbl by CIN85,
thereby inhibiting the internalization of the EGFR [159, 58, 93, 43].
The oligomerization state of CIN85 itself plays also a role for its interactions. A CIN85 variant lacking
the CC domains, which abolishes CIN85 trimerization, is not recruited to the plasma membrane after
BCR stimulation [18]. This indicates that its affinity to SLP65, c-Cbl and other BCR-recruited protein
is too low to allow an stable interaction. Zhang and colleagues showed this effect for the CIN85-c-Cbl
interaction by co-immunoprecipitation. The CIN85-c-Cbl interaction was strongly reduced for a CIN85
variant lacking the CC in comparison to CIN85-wt [200].
Besides the concentration of the interaction partners, a further layer of control might be added by
their post-translational modifications. It has been reported that the affinity of CIN85 to its ligands can
be modulated by their modification. Different influences of phosphorylation have been described. The
interaction of CIN85 with c-Cbl has been reported to increase after BCR stimulation, correlating with
enhanced c-Cbl phosphorylation. [20]. The tyrosine phosphorylation of the ESCRT-I complex subunit
MVB12A facilitates its interaction with CIN85 [89]. In contrast, threonine phosphorylation of endophilin
A1, serine phosphorylation of Dab1 and tyrosine phosphorylation of Alix reduce their affinity to CIN85
[80, 153, 158]. Because SLP65 is heavily phosphorylated at tyrosine, serine and threonine residues dur-
ing its activation upon BCR stimulation [122], this might affect its affinity to CIN85. Once SLP65 has
reached its destination, the BCR, and is phosphorylated by Syk, further SLP65 clustering by CIN85
might be dispensable. The dissolution of the SLP65-CIN85 complex at the BCR could be useful because
it might increase the steric accessibility of phosphorylated SLP65 for the new interaction partners. On
the other hand, it is possible that the SLP65-CIN85 clusters remain constant to stabilize the emerging
microsignalosomes. It has been shown that CIN85 can interact with unphosphorylated and phosphory-
lated SLP65 [189, 121]. However, an exact determination of the affinities to both forms is still missing.
Also CIN85 itself can be modified to modulate its interactions. It has been shown that tyrosine phospho-
rylation of CIN85 can occur by Src [160]. This phosphorylation affects the tyrosine residues Y10, Y109,
Y271 and Y278 which are located in the SH3 domains and might thus influence the SH3 domain-mediated
interaction of CIN85. Possible modifications of CIN85 after BCR stimulation have not been studied yet.
5.3 Inhibiton of complex formation by intramolecular CIN85 interactions
Another layer of regulation of CIN85 complex formation might be the autoinhibitory capability of CIN85.
The first and second SH3 domain of CIN85 have been shown to bind intramolecularly to a PPKKPR
motif in the PRR of CIN85 [17, 92, 179]. This means that the CIN85 SH3 domains would be no longer
available to mediate interactions with other proteins resulting in loss of CIN85 clustering function. The
autoinhibition might be even enhanced by CIN85 oligomerization, as proposed by Havrylov and col-
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leagues who speculated that in a CIN85 oligomer, the SH3 domains of one CIN85 molecule would bind
to the PPKKPR motif of another [64]. Deletion of the CIN85 region containing this motif leads to more
efficient binding of CIN85 to c-Cbl [179]. Besides the competition with other interaction partners, the
intramolecular interaction of CIN85 might provide a hurdle to cluster CIN85 interaction partners that
are not locally pre-concentrated, like SLP65-∆N. For effective complex formation, the autoinhibiton of
CIN85 has to be overcome by offering a high concentration of binding sites for CIN85.
Interestingly, it seems also possible to overcome the intramolecular binding of CIN85 by expression of
CIN85 at very high levels. In cells heavily overexpressing fluorescently tagged CIN85, there are large
aggregate-like dots of the tagged CIN85 protein ([189, 199] and own unpublished observation). At high
intracellular CIN85 concentrations, the intermolecular CIN85 binding might be favored. The binding of
the SH3 domains of one CIN85 molecule to the PRR of another would result in the formation of very
large CIN85 clusters. These aggregates are not translocated to the plasma membrane upon either BCR
or latrunculin stimulation (own unpublished observations) or influenced by EGF stimulation [199]. This
suggests that they are non-functional and do not take part in signaling processes.
The influence of the autoinhibitory function of CIN85 might be assessed by comparison with its paralog
CD2AP. CD2AP does not possess this intramolecular SH3 domain binding site due to an R to T exchange
in the PPKKPR motif. Consistently, overexpression of CD2AP does not induce the formation of large
aggregates that are observed for CIN85 [18]. In contrast to CIN85, CD2AP is partially pre-recruited
to the plasma membrane in resting B cells [18]. These differences could be explained by the lack of
autoinhibiton of CD2AP. This would allow the binding of other molecules to the CD2AP SH3 domains,
even if the interaction partners are not pre-concentrated. Compared to CIN85, the lower specificity of
CD2AP interactions might impair the capability of CD2AP to induce the formation of large complexes.
This could explain the minute influence of CD2AP on BCR signaling despite its individual SH3 domains
have an affinity to SLP65 that seems to be in the same range as the affinity of the CIN85 SH3 domains
[121]. Another explanation for the differences between CIN85 and CD2AP localization could be the
actin binding sites of CD2AP which are not present in CIN85 [83, 179, 48]. The binding to actin might
sequester CD2AP from the sites of SLP65 pre-concentration. It would be interesting to see if a mutant
of CIN85 without the intramolecular binding site would be still able to mediate efficiently the formation
of SLP65 complexes.
5.4 The influence of SLP65 and CIN85-CC lipid binding
While the membrane association of SLP65 due to its N-terminus is crucial for the SLP65-CIN85 complex
formation (see 5.2), the PA-association of the CIN85-CC seems to be dispensable. Zhang and colleagues
showed that deletion of the CIN85-CC results in loss of PA binding and membrane association of CIN85
[200] and demonstrated in a follow-up work that deletion of the CC results also in loss of endosomal
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localization of CIN85 [201]. Furthermore, they showed that the CIN85-CC-PA interaction depends on
four basic amino acids in the CC [201]. The exchange of these amino acids for alanine abolished PA bind-
ing, but also oligomerization of CIN85 [201] which made it impossible to distinguish between these two
mechanisms in their studies. In B cells, it would be possible that the CIN85-CC directs SLP65 to specific
membranes within the Golgi apparatus due to its PA association. PA has been shown to be present in the
Golgi apparatus complex where it is produced by phospholipase D2 [147]. However, there are arguments
against the importance of CIN85-PA binding for SLP65 function. The PA binding is conserved in the
monomeric CIN85-CC variant L619K which does not support SLP65-mediated Ca2+ influx (Figure 4.21).
The CC of CD2AP, which does not bind to PA (Figure 4.23), supports SLP65-mediated Ca2+ influx as
well as the CIN85-CC (Figure 4.22). SLP65 function can also be supported by the SCOC-CC and by the
Venus protein both of which are not related to the CIN85-CC (Figure 4.23 and Figure 4.29). It is not
known that the SCOC-CC exhibits the same PA binding function as CIN85 and it is hard to imagine that
the YFP variant Venus binds to PA. Furthermore, the specific PA binding motif of Raf is not sufficient
to substitute the CIN85-CC in chimeric proteins (Figure 4.16). All these results point in the direction
that PA binding of the CIN85-CC is not required for its function on SLP65.
5.5 The chronological order of SLP65-CIN85 complex formation
Based on our results and the previous considerations, I developed the model of SLP65-CIN85 complex
formation shown in Figure 5.1. In a first step, SLP65 molecules can associate to membranes due to the
SLP65 N-terminus, as shown by our group [40]. Subsequently, the high local concentration of SLP65
will overcome the autoinhibition of CIN85 which allows binding of CIN85 to multiple SLP65 molecules
(b). The bridging of several SLP65 molecules can additionally stabilize their membrane association.
The lipid binding affinity of the SLP65 N-terminus might be relatively low. Oligomerization of SLP65
by CIN85 can enhance the membrane binding by the creation of larger SLP65 complexes with multiple
membrane binding sites and thus high avidity. This could explain why not only the deletion of the SLP65
N-terminus but also the disruption of the SLP65-CIN85 interaction reduces SLP65 membrane association
(Figure 4.3). Due to its multiple CIN85 binding motifs, each SLP65 molecule can recruit multiple CIN85
molecules to the emerging complex; free CIN85 SH3 domains can recruit additional SLP65 molecules (c).
This results in the formation of large membrane-associated SLP65-CIN85 complexes (d). One assembly
site of these complexes are ATP-containing, VAMP7-positive vesicles. The idea of a membrane associated
pool of SLP65 which takes part in signaling was already proposed by Koretzky et al. in 2006, interpreting
results by Koehler et al. [90]. My results support this theory, explaining additionally the important role
of CIN85 in the assembly of membrane-associated SLP65 complexes.
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Fig. 5.1: Complex formation of SLP65 and CIN85 at vesicular membranes. The SLP65 N-terminus
associates to lipids, recruiting SLP65 to intracellular membranes (a). The high local concentration of
CIN85 binding sites (black ovals) allows binding of a CIN85 trimer to membrane associated SLP65 (b). For
this process, it is necessary to overcome the autoinhibitory intramolecular CIN85 SH3 PRR interaction.
Due to their multiple binding sites, CIN85 and SLP65 recruit additional CIN85 and SLP65 molecules




5.6 The regulation of oligomerization as a general feature in signaling path-
ways
The concept of adaptor protein-induced oligomerization might not be restricted to the SLP65-CIN85
interaction. I could show that the T-cell homolog of SLP65, SLP76, has to be oligomerized to function in
BCR signaling. The mechanism of action of SLP76 seems to differ from the one of SLP65, it assembles
the Ca2+ initiation complex not by SH2 domain-pY but by SH3 domain-PRR-mediated recruitment of
PLC-γ (reviewed in [90]). Nevertheless, for its function in B cells it needed oligomerization, which could
be artificially provided by interaction with CIN85 (introduction of CIN85 binding sites [121] or direct
fusion to CIN85-CC (Figure 4.27)).
Because SLP76-wt harbors no CIN85 interaction sites, it would be interesting to see if it can undergo
oligomerization by other means in physiological situations. Oligomerization, probably mainly dimer-
ization, of SLP76 upon TCR stimulation has been described. The oligomerization is mediated by the
N-terminal SLP76 SAM domain [102]. However, SAM domain-mediated dimerization could be not ob-
served in B cells for chimeric SLP76-SAM-SLP65-∆N proteins (S. Pirkuliyeva, unpublished data). The
reason could be that SAM oligomerization depends on a TCR-triggered process like a post-translational
modification of SLP76 that cannot be triggered by the BCR. It is also possible that the SAM-mediated
oligomerization depends on interactions with additional proteins that are not expressed in B cells.
Coussens and collegues stated that adaptor protein-mediated oligomerization of SLP76 is needed for its
physiological function in TCR signaling [30]. This oligomerization is mediated by the adhesion and
degranulation-promoting adaptor protein (ADAP), also known as FYN-binding protein (FYB). The
SLP76-ADAP interaction is required for efficient recruitment of SLP76 to microsignalosome, PLC-γ1
activation and Ca2+ mobilization [30]. ADAP contains three binding sites for the SLP76 SH2 domain
and can potentially trimerize SLP76 [50, 14, 99]. It was shown that at least two binding sites are needed
to support SLP76 function, indicating the requirement of simultaneous binding of two or three SLP76
molecules [30]. ADAP is expressed in T cells, but not in B cells [31], providing one possible explanation
why SLP76 cannot substitute for SLP65.
Interestingly, ADAP contains one SH3 domain and one CC [31]. The CC might enable further ADAP
oligomerization, though this has not been studied yet. ADAP has been shown to be crucial for the
NfκB activation in TCR signaling [109, 167], like CIN85 in BCR signaling [88]. Furthermore, ADAP
has also been shown to interact with c-Cbl [124]. Even though the proteins ADAP and CIN85 are not
related, these fascinating parallels indicate that the two molecules have adapted similar roles in TCR
respectively BCR signaling. In this homology model, a pre-concentration of SLP76 by the oligomeriza-
tion of its SAM domain might substitute for the pre-concentration mediated by the SLP65 N-terminus.
As already mentioned, SLP76 expressed in SLP65-deficient B cells needs additional adaptor protein
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mediated-oligomerization to function in BCR signaling, either by the introduction of CIN85 binding sites
[121] or by coexpression of LAT [196]. SLP65 expressed in SLP76-deficient T cells does not need the coex-
pression of additional adaptor proteins, probably because CIN85 is expressed in T cells. It requires only
the expression of the kinase Syk [2], maybe because it cannot be efficiently phosphorylated by ZAP70,
the T cell homolog of Syk. Table 5.1 gives an overview of similar and different properties of the two
adaptors CIN85 and ADAP in BCR respectively TCR signaling.
Tab. 5.1: Comparison between CIN85 and ADAP in BCR respectively TCR signaling
Function CIN85 ADAP




Number of interaction sites
present in CIN85/ADAP
3 (SH3 domains) 3 (phospho-tyrosines)
Number of interaction sites
present in SLP65/SLP76
2 or 3 1 1 (SH2 domain)
c-Cbl binding yes yes
Involvement in NfκB signaling yes, by unknown
mechanism
yes, by recruitment of TAK1 to
the CBM complex
Oligomerization by CC domain yes possible
Expression in B cells yes no
Expression in T cells yes yes
The importance of adaptor protein oligomerization has been described for other signaling pathways, in
particular the NfκB pathway (reviewed in [66]). Oligomerization of the Inhibitor of κB kinase (IKK)
is crucial for its activation which is thought to occur by trans auto-phosphorylation. The platform
of IKK oligomerization is provided by oligomerized adaptor proteins [66]. The IKK binding protein
NEMO can form trimers [3] or tetramers [178, 35] due to its CC domain. Constitutive oligomerization
of NEMO or IKK components by fusion to FK506 binding protein domains is sufficient to activate IKK
[74, 137]. The oligomerization of NEMO is controlled by different mechanisms, by the NEMO-intrinsic
N-terminal dimerization domain, by the C-terminal CC domain and by its interaction with the kinase
RIP1 [74, 106, 35]. This resembles the dually regulated oligomerization of SLP65 by its N-terminus and
CIN85 binding that was found in this work.
1The binding of CIN85 to the first of the three PXXXPR motifs in SLP65 is weak in vitro. The disruption of this binding




The activation of NfκB upon BCR and TCR signaling depends on the formation of the CARD11-BCL10-
MALT1 (CBM) complex that is required for the activation of IKK (reviewed in [186]). The formation of
the functional CBM complex requires multiple oligomerization steps. CARD11 induces BCL10 oligomer-
ization [138]. The oligomerization and subcellular localization of CARD11 itself are controlled by its CC
domain [177]. Disruption of the CC-mediated oligomerization results in impaired CARD11 function. On
the other hand, it was shown that homo-oligomerization of the CARD domains of CARD11 can impair
their interaction with BCL10, thereby preventing the formation of a functional CBM complex [128]. This
indicates again that the oligomerization state of adaptor proteins is crucial to control their function in
signaling pathways. There can be multiple layers of oligomerization that control the formation of one
complex, like CARD11 and BCL10 oligomerization for the CBM complex or CIN85 and SLP65 for the
Ca2+ initiation complex.
Regulation of the oligomerization state has also been described for bacterial protein ClpC which is in-
volved in proteolysis. Its function depends on its oligomerization by the adaptor protein MecA [84]. This
shows that adaptor protein-mediated control of the oligomerization state is an evolutionary very ancient
principle.
5.7 The transport of SLP65 and CIN85 to the plasma membrane
My data strongly suggests that SLP65 oligomerization mediated by CIN85 is required for SLP65 function.
From the point of utility, SLP65 multimerization makes a lot of sense. Because SLP65 does not contain
an enzymatic function, the activation of multiple SLP65 molecules at the same time is its only way for
SLP65 to provide signal amplification. The pre-assembly of large SLP65-CIN85 complexes in resting
cells enables the cell to react faster and more efficiently to BCR stimulation. However, it remains to be
elucidated how multimerization of SLP65 facilitates recruitment of the SLP65 complexes to the plasma
membrane and the BCR.
It is possible that the site of the complex assembly, a specific type of ATP-containing vesicles, positive
for VAMP7 [40], is important for the following transport process to the plasma membrane and the BCR.
The translocation of the SLP65-CIN85 complexes could occur by vesicular transport, triggered by BCR
stimulation. This raises the question how the specificity of the SLP65-CIN85 complexes for these vesicles
is obtained. Assuming that the function of CIN85 is only the multimerization of SLP65, the targeting
function should be inherent to SLP65. It cannot be located in the N-terminus because highly oligomerized
SLP65 variants are not dependent on the N-terminus for the formation of complexes, observed as dot-like
structures by confocal microscopy (Figure 4.10, Figure 4.22 and Figure 4.29). Furthermore, the presence
of SLP65 in dot-like structures did not require a functional SH2 domain (Figure 4.14). This leads to the
conclusion that the vesicle-targeting feature of SLP65 resides in its central proline rich part (aa 46-345).
This is consistent with the observation that the exchange of the central part for an unstructured glycine-
serine linker resulted in the loss of dot-like location of the protein [136]. The central part of SLP65 has
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been shown to be intrinsically disordered by NMR spectroscopy (unpublished data by L. Wong, L. Russo
and [136]). So it does not contain a structured domain that could recruit SLP65 to vesicles, e.g. by lipid
binding. The interactome of SLP65 has been studied by mass spectrometry [121]. SLP65 can interact
with Unc119, a protein implicated in trafficking of myristoylated proteins to specific membrane compart-
ments [26] and endosomal targeting of proteins in T cells [54]. Unc119 has been found to be important
for TCR signaling [53], its role in B cells has not been studied yet. It could be a potential candidate
molecule for the recruitment of SLP65 to specific vesicles. The VAMP7-positve vesicles might serve as a
starting platform for plasma membrane recruitment by vesicular transport. The vesicle transport process
might require cytoskeletal rearrangements like actin depolymerization that occurs upon BCR stimulation
[60].
For the anchoring of SLP65 complexes to the BCR, the avidity of the SLP65 SH2 domains might play
a major role. Covalent SLP65 oligomerization by chimeric proteins of SLP65 with split Venus could not
substitute for the function of the SLP65 SH2 domain (Figure 4.30), indicating that the SH2 domain
does not take part in SLP65 oligomerization but in a sequential process. The inactivation of the SLP65
SH2 domains preserved the dot-like localization of chimeric CIN85-CC-SLP65 proteins, but it abolished
stable plasma membrane localization upon BCR stimulation and thus Ca2+ signaling (Figure 4.16). This
suggests again that the SLP65 SH2 domain might be involved in anchoring SLP65 to the BCR, not the
initiation of its translocation to the plasma membrane.
The SLP65 SH2 domain can bind to pY204 in Igα [42, 79]. This interaction could be crucially dependent
on the avidity of the SLP65 SH2 domains and thus on the SLP65 oligomerization state. It is astonishing
that the SLP65-CIN85 interaction is strongly required for SLP65 BCR recruitment and Ca2+ signaling
upon stimulation with 0.2 µg/ml α-IgM, while its influence is not that pronounced upon stimulation
with 2 µg/ml α-IgM (Figure 4.1). This could be explained by modification of the activation threshold by
different extents of Igα phosphorylation. Upon stimulation with 0.2 µg/ml α-IgM, only a minor portion
of Igα can be phosphorylated, large SLP65 complexes with high SH2 domain avidity would be required to
enable a stable interaction and thereby effective BCR anchoring. Stimulation with 2 µg/ml α-IgM would
result in higher Igα phosphorylation, also smaller SLP65 complexes with lower avidity might mediate
efficient binding, BCR anchoring and thus signaling. This model fits to an effect I observed for chimeric
SCOC-CC-SLP65 proteins of different oligomerization states (Figure 4.26). The difference in Ca2+ influx
between dimeric, trimeric and tetrameric increased with decreasing α-IgM concentrations.
The requirement for high avidity of SH2 domain binding has been reported before. The two SH2 do-
mains of Syk bind in tandem much more effective to ITAMs than individually [164]. Also other signaling
proteins like ZAP70, PLC-γ, SHP2 and the PI3K subunit p85 possess tandem SH2 domains [126, 9],
indicating a general need of bi- or multivalent interactions for SH2 domains. While single SH2 domains
bind to pY-peptides with a micromolar affinity, tandem SH2 domains can bind to bi-pY-peptides with
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nanomolar affinity [126]. This demonstrates the enormous power of affinity enhancement by avidity.
There might be also other additional mechanisms which could anchor SLP65 to the plasma membrane.
Some membrane protein ligands linking SLP65 to the BCR have been proposed in the past, like the
tetraspanning membrane protein CMTM7 [111]. However, we were not able to confirm the association of
SLP65 with this or other membrane proteins ([121] and own unpublished data). If interactions of SLP65
with other membrane proteins than Igα are physiologically relevant, they could also be influenced by
SLP65 multimerization and thus by CIN85. So the oligomerization of SLP65 by CIN85 serves at least
two purposes: It mediates the association of SLP65 to specific vesicles by a hypothetic targeting device
in the SLP65 central region and allows efficient BCR targeting of SLP65 complexes by amplifying the
avidity of the SLP65 SH2 domains. A model of SLP65 recruitment to the BCR and the involvement of
CIN85 is given in Figure 5.2.
5.8 The overall effect of CIN85 expression in B cells
Having shown the importance of CIN85 for the function of SLP65, it is intriguing that there are differ-
ent reports on the influence of CIN85 on BCR signaling. Experiments of our group have shown that
the knockdown of CIN85 in chicken DT40 B cells and the knockout of CIN85 in human Ramos B cells
result in a modest reduction in Ca2+ signaling ([121, 18] and unpublished observations K. Schulz). This
corresponds with the reduced efficiency of SLP65 BCR recruitment in these cells due to loss of SLP65
clustering. However, the effect of reduced CIN85 expression is weaker than the reduction of Ca2+ sig-
naling that occurs in SLP65-deficient cells reconstituted with the CIN85 binding deficient SLP65 mutant
M2,3 (Figure 4.1 and [121]). Niiro and colleagues reported that CIN85 knockdown in the human Burkitt
lymphoma cell line BJAB even increases BCR signaling while overexpression of CIN85 decreases BCR-
induced phosphorylation and expression level of Syk, phosphorylation of PLC-γ2 and Ca2+ influx [119].
We could not confirm these results in DT40 or Ramos B cells where CIN85 overexpression had no effect
on BCR signaling (own unpublished observations). For human primary B cells, Niiro and colleagues
reported that the knockdown of CIN85 enhances survival, growth and differentiation [119]. Recently,
our group was able to identify a patient that carries a deletion in the CIN85 gene, resulting in the loss
of CIN85 protein expression (unpublished observation). This patient showed a modestly reduced Ca2+
signaling and a severe block of BCR-induced NfκB activation upon BCR stimulation. This corresponds
partially with results obtained from a mouse strain harboring a B cell specific CIN85 deficiency [88].
These mice show impaired NfκB activation and loss of B1a cells while the Ca2+ signaling in B2 cells is
not affected.
These different observations concerning CIN85 deficiency in B cells could be explained by the promis-
cuity of CIN85 interactions. As a potent oligomerizer, CIN85 would enhance the functions of several
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Fig. 5.2: Model for plasma membrane recruitment of SLP65 and CIN85. Large SLP65-CIN85 complexes
are localized on VAMP+ ATP-containing vesicles (Figure 5.2). Upon BCR stimulation, the vesicles are
translocated to the membrane, were the SLP65 complexes can be anchored to the BCR by the interaction
of the SH2 domains to pY204 in Igα. This anchoring allows multiple phosphorylations of the whole SLP65
complex by Syk. The phosphorylated complex provides an extended platform for the assembly of signal-
transducing molecules like Btk and PLC-γ2. The CIN85 molecules in the complex can interact with
other proteins in the proximity of the activated BCR, e.g. SHIP1 and p85. This might modulate the
function of these CIN85 interactors. Additionally, these interactions could provide additional membrane
anchoring for the SLP65-CIN85 complex and stabilize the emerging microsignalosomes.
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interaction partners given that they are present in a concentration that enables a stable interaction. In
many cases, CIN85 seems to be a general enhancer of the function of its ligands. CIN85 associates with
the GTPase ARAP1, coexpression of these two proteins leads to localization of ARAP1 in dot-like struc-
tures. The knockdown of ARAP1 accelerates trafficking and degradation of the EGFR, the knockdown
of CIN85 has the same effect [199]. CIN85 associates also with the GTPase dynamin 2, both proteins
are localized in dot-like structures supposed to be endosomes [161]. Dynamin 2 influences trafficking
of proteins in late endosomes, a knockdown of either dynamin 2 or CIN85 delays EGFR degradation
[161]. CIN85 associates with the GTPase ASAP1 which is known to play a role in invasion of breast
cancer cells [125]. Both proteins were found to colocalize in invadopodia of breast cancer cells [117]. The
chemoinvasion activity of these cells is inhibited by knockdown of ASAP1 or CIN85 or by disruption of
their interaction [117]. Beside these reports, which can be explained by mere functional enhancement by
CIN85-mediated clustering, CIN85 has been shown to regulate protein activity by competition with other
interaction partners. It reduces the association of c-Cbl with Sts1, a negative regulator of c-Cbl activity,
by competitive binding which results in decreased Syk activity by increased c-Cbl activity [130]. On the
other hand, association of Septin 9 with CIN85 reduces the CIN85-c-Cbl interaction, leading to a delay of
EGFR degradation by decreased c-Cbl activity [34]. The only example for direct negative regulation of a
protein function by CIN85 is its effect on the PI3K [55]. It was shown that the rat homolog of CIN85 can
inhibit the PI3K activity in vitro by binding to the PI3K regulatory subunit p85 [55]. This interaction is
mediated by the p85 SH3 domain and the CIN85-PRR. It was further demonstrated that the inhibition of
PI3K by CIN85 can induce apoptosis in neurons. Interestingly, this effect was also exhibited by a CIN85
variant lacking the CC [55]. So this might be a functional different mechanism of CIN85, not mediated by
protein clustering by the SH3 domains. In CIN85-deficient B cells, the loss of PI3K inhibiton by CIN85
could potentially compensate for missing clustering of activators of the BCR signaling. It might lead to
higher Akt and Btk activity by increased PIP3 levels.
Some of the CIN85 interactors are activators for BCR signaling, like SLP65, some of them are inhibitors,
like c-Cbl and SHIP1. Because CIN85 can potentially enhance the functions of all of them and because
these enhancements are competitive, the overall outcome of CIN85 absence might mainly depend on the
expression levels of the different interaction partners. This complicates the prediction of the effect of
increased or decreased CIN85 expression. It would probably require an exact bioinformatic model and
information of the concentration of all CIN85 interaction partners. In contrast, the specific loss of only
one CIN85 interaction has a more straightforward effect. The disruption of the SLP65-CIN85 interac-
tion in SLP65-deficient cells reconstituted with the CIN85 binding deficient variant SLP65-M2,3 shows
a stronger phenotype than a complete CIN85 knockout. The explanation for this effect is that these
cells lack only one positive, but not the negative, effects of CIN85 on BCR signaling. In addition, the
SLP65-M2,3 variant cannot bind to the CIN85 homolog CD2AP which might partially compensate for
this loss of CIN85.
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The main readout in my experiments was the BCR-induced Ca2+ influx in DT40 B cells. In this model
system, Ca2+ signaling can be regarded as an almost analog event. It will happen at a certain threshold of
activation, but once the threshold is reached, the amount of Ca2+ influx into one cell seems to be always
comparable, independent of the strength of the external stimulus (i.e. α-IgM concentration). Differences
in the measured Ca2+ signals are generated by the different amount of cells reaching the threshold for
Ca2+ influx. In this respect, CIN85 could act as modulator of this threshold. When positive regulators
amongst CIN85 interactors dominate, CIN85 would increase Ca2+ signaling by lowering the threshold.
When negative regulators amongst CIN85 interactors dominate, CIN85 would decrease Ca2+ signaling
by raising the threshold. Nevertheless, the CIN85-deficient patient gives us the hint that CIN85 is a
positive regulator of BCR signaling in a physiological situation. The patient displayed very low levels of
IgM and IgG4 in the serum, indicating a defect in B cell activation, especially because his T cells seem
to be activated normally (unpublished observations).
5.9 Conclusion
In this work, it could be shown that the interaction of CIN85 with SLP65 enables efficient BCR signaling
due to CIN85-mediated multimerization of SLP65. The N-terminus of SLP65 is crucial for this multimer-
ization. It can increase the local concentration of SLP65 on membranes which would allow the efficient
formation of large SLP65-CIN85 complexes. SLP65 multimerization is essential for the recruitment of
SLP65 to the BCR, probably by enhancing the avidity of the SLP65 SH2 domain and a hypothetical other
function in the middle part of SLP65. The general concept of adaptor protein-mediated oligomerization
can also be transferred to the SLP65 homolog in T cells, SLP76. SLP76 has been shown to oligomerize
due to its interaction with the adaptor protein ADAP [30]. The oligomerization of SLP-adaptors seems
to be a fundamental principle in lymphocyte signaling. With regards to SLP65, this thesis demonstrates
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Nemo trimerizes through its coiled-coil c-terminal domain. Journal of Biological Chemistry 277, 20
(2002), 17464–17475.
[4] Antony, P., Petro, J. B., Carlesso, G., Shinners, N. P., Lowe, J., and Khan, W. N.
B cell receptor directs the activation of nfat and nf-κb via distinct molecular mechanisms. Experi-
mental cell research 291, 1 (2003), 11–24.
[5] Aronheim, A., Engelberg, D., Li, N., Al-Alawi, N., Schlessinger, J., and Karin, M.
Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling
pathway. Cell 78, 6 (1994), 949–961.
[6] Baba, T. W., Giroir, B. P., and Humphries, E. H. Cell lines derived from avian lymphomas
exhibit two distinct phenotypes. Virology 144, 1 (1985), 139–151.
[7] Baba, Y., Hashimoto, S., Matsushita, M., Watanabe, D., Kishimoto, T., Kurosaki,
T., and Tsukada, S. Blnk mediates syk-dependent btk activation. Proceedings of the National
Academy of Sciences 98, 5 (2001), 2582–2586.
[8] Bao, M., Hanabuchi, S., Facchinetti, V., Du, Q., Bover, L., Plumas, J., Chaperot, L.,
Cao, W., Qin, J., Sun, S.-C., et al. Cd2ap/ship1 complex positively regulates plasmacytoid
dendritic cell receptor signaling by inhibiting the e3 ubiquitin ligase cbl. The Journal of Immunology
189, 2 (2012), 786–792.
[9] Barua, D., Faeder, J. R., and Haugh, J. M. Computational models of tandem src homology 2
domain interactions and application to phosphoinositide 3-kinase. Journal of Biological Chemistry
283, 12 (2008), 7338–7345.
[10] Behrens, C., Binotti, B., Schmidt, C., Robinson, C. V., Chua, J. J. E., and Kühnel,
K. Crystal structure of the human short coiled coil protein and insights into scoc-fez1 complex
formation. PloS one 8, 10 (2013), e76355.
95
REFERENCES
[11] Berridge, M. J. Inositol trisphosphate and calcium signalling. Nature 361, 6410 (1993), 315–325.
[12] Bethani, I., Lang, T., Geumann, U., Sieber, J. J., Jahn, R., and Rizzoli, S. O. The
specificity of snare pairing in biological membranes is mediated by both proof-reading and spatial
segregation. The EMBO journal 26, 17 (2007), 3981–3992.
[13] Bezsonova, I., Bruce, M. C., Wiesner, S., Lin, H., Rotin, D., and Forman-Kay, J. D.
Interactions between the three cin85 sh3 domains and ubiquitin: Implications for cin85 ubiquitina-
tion. Biochemistry 47, 34 (2008), 8937–8949.
[14] Boerth, N. J., Judd, B. A., and Koretzky, G. A. Functional association between slap-130
and slp-76 in jurkat t cells. Journal of Biological Chemistry 275, 7 (2000), 5143–5152.
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The proteome of VAMP7-containing vesicles in DT40 cells was determined by SILAC-based mass spec-
trometry. A plasmid coding for Cerulean-tagged VAMP7 was introduced inDT40 cells by retroviral
transduction. The cells were labeled by growing them in SILAC medium containing the heavy isotope
labeled amino acids lysine+4 and arginine+6. As a control, DT40 cells transduced with eGFP were grown
in medium with light amino acids. The differently labeled cells were mechanically disrupted by passing
them through a Balch homogenizer (Figure 4.5). The PNS subjected to affinity purification with α-GFP
antibodies. In the end, the light and heavy labeled samples were pooled in a 1:1 ratio and subsequently
analyzed by mass spectrometry. The experiment was repeated 4 times, proteins appearing at least 3
times at a heavy to light ratio of 2 or higher were regarded as component of the vesicular proteome.
V
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X any amino acid
Y Tyrosine














ADAP adhesion and degranulation promoting adaptor protein
ADAP2 Arf-GAP with dual PH domain-containing protein 2
ADCC antibody-dependent cellular cytotoxicity
Akt AKR mouse transforming
Alix ALG-2-interacting protein X
ALKBH2 α-ketoglutarate-dependent dioxygenase alkB homolog 2
AP affinity purification
APC/C anaphase promoting complex/cyclosome
APS ammonium persulfate
ARAP1 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1
ARHGAP17 Rho GTPase-activating protein 17
ASAP1 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1
ASC apoptosis-associated speck-like protein containing a CARD
ATP adenosine triphosphate
BASH B cell adaptor containing SH2 domain
bca B cell activation
BCL10 B-cell lymphoma/leukemia 10
BCR B cell receptor
BiFC Bimolecular fluorescence complementation
bleo bleomycin resistance
BLNK B cell linker
BSA bovine serum albumin
Btk Bruton’s tyrosine kinase
C domain constant domain
C2 Protein kinase C conserved region 2
Ca2+ calcium2+ ion
CapZ capping protein (actin filament) muscle Z-line
CARD11 caspase recruitment domain-containing protein 11
Cbl Casitas B-lineage lymphoma
CBM CARD11-BCL10-MALT1
CC coiled-coil
CC C-terminal half of CIN85 coiled-coil domain
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CCDC88B coiled-coil domain-containing protein 88B
CD cluster of differentiation
CD2AP CD2-associated protein
CDC complement-dependent cytotoxicity
CDC21 cell division cycle 21
CH Ig heavy chain constant domain
CIN85 Cbl-interacting protein of 85 kDa
CIP calf intestinal phosphatase
Cit Citrine
CLEC17a C-type lectin 17a
ClpC ATP-dependent Clp protease subunit C
CMTM7 CKLF-like MARVEL transmembrane domain-containing protein 7
CN N-terminal half of CIN85 coiled-coil domain
COPI coat protein complex I
Crk CT10 Regulator of Kinase
Cyt cytosol
D segment diversifying segment
Dab2 disabled homolog 2
DAG diacyl-glycerol
∆N devoid of the N-terminal region





E. coli Escherichia coli
ECL enhanced chemical luminescence
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EGFR epidermal growth factor receptor
eGFP enhanced green fluorescent protein
ER endoplasmic reticulum
ERK extracellular signal-regulated kinase
ESCRT-I endosomal sorting complex required for transport I
ESI electrospray ionization
F(ab’)2 bivalent antigen binding fragment
VIII
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FBXO28 F-box only protein 28
Fc fragment crystallizable
FcαR Fc α Receptor
FcγR Fc γ Receptor
FcεR Fc ε Receptor
FcR Fc Receptor
FCS fetal calf serum
fw forward
FYB FYN-binding protein
GADS GRB2-related adaptor protein 2
GAP GTPase activating protein
GFP green fluorescent protein
GM130 130 kDa cis-Golgi matrix protein






HUS1 checkpoint protein HUS1
Ig immunoglobulin
IgSF immunoglobulin super-family
IKK Inhibitor of κB kinase
INDO-1 AM INDO-1 acetoxymethylester
IP3 inositol trisphosphate
IPTG isopropyl-β-D-thiogalactopyranoside
ITAM immunoreceptor tyrosine-based activation motif
ITT immunoreceptor tail tyrosine
J segment joining segment
JNK c-Jun N-terminal kinase
kB kilobasepair
kDa kilodalton
LAMP1 lysosome-associated membrane glycoprotein 1





Lyn Lck/yes-related novel protein tyrosine kinase
M2,3 CIN85 binding motifs 2 and 3
MALLS multiangle laser light scattering
MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1
MAPK mitogen activated protein kinase
MecA methicillin resistance determinant A
MIRab13 molecule interacting with Rab13
MIRR multichain immune recognition receptor
mRNA messenger ribonucleic acid
mTOR mechanistic target of rapamycin
MVB12A multivesicular body subunit 12A
N-BAR N-terminal Bin-Amphiphysin-Rvs
NEMO NFκB essential modulator
NFAT nuclear factor of activated T cells
NfκB nuclear factor of κ light polypeptide gene enhancer in B cells
NLRP3 NACHT, LRR and PYD domains-containing protein 3
NMR nuclear magnetic resonance
OSBP1 oxysterol-binding protein 1
p110 phosphatidylinositol 3-kinase 110 kDa catalytic subunit
p38 mitogen-activated protein kinase p38
p85 phosphatidylinositol 3-kinase 85 kDa regulatory subunit
PA phosphatidic acid
PAGE polyacrylamide gel electrophoresis
PBS phosphated buffered saline










pY phosphorylated tyrosine residue
Rab5 Ras-related protein Rab5
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Raf1 rat fibrosarcoma proto-oncogene serine/threonine-protein kinase
Raf-PA Raf1 phosphatidic acid binding motif
RAG recombination activating gene
Ras GTPase rat sarcoma
RASAL2 Ras GTPase-activating protein nGAP
rev reverse
RIP1 receptor-interacting serine/threonine-protein kinase 1
RL arginine-to-leucine exchange in the SLP65 SH2 domain
RNA ribonucleic acid
RPMI Roswell Park Memorial Institute
RSS recombination signal sequences
RT room temperature
Ruk regulator of ubiquitous kinase
SAM sterile α motif
SCOC short coiled-coil protein
SDS sodium dodecyl sulfate
SETA SH3 domain containing gene expressed in tumorigenic astrocytes
SH2 src homology 2
SH3 src homology 3
SH3BP1 SH3 domain-binding protein 1
SHP2 SH2 domain-containing phosphatase 2
SHIP1 SH2 domain-containing inositol phosphatase 1
SHKBP1 SH3KBP1-binding protein 1
SILAC stable isotope labeling by amino acids in cell culture
SIPA1 signal-induced proliferation-associated protein 1
SLP65 SH2-domain containing leukocyte protein of 65 kDa
SLP76 SH2-domain containing leukocyte protein of 76 kDa
SNARE soluble NSF attachment protein receptor
SOC store-operated Ca2+ channel
SOS son of sevenless
Src rous sarcoma oncogene
STAP1 signal-transducing adaptor protein 1
STIM stromal interaction module
Syk spleen tyrosine kinase
TAE Tris acetate EDTA buffer
TBC Tre-2, Bub2p, and Cdc16p
XI
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TBS Tris buffered saline
TBS-T Tris buffered saline-Tween
TCR T cell receptor
TdT terminal deoxynucleotidyl transferase
Tec tyrosine kinase expressed in hepatocellular carcinoma
TEMED tetramethylethylenediamine
TGN trans-Golgi network
TIRAP Toll-interleukin 1 receptor domain-containing adaptor protein
TRIM62 tripartite motif-containing protein 62
Tris tris(hydroxymethyl)-aminomethane
tSH2 tandem SH2
V domain variable domain
V segment variable segment
VAMP7 vesicle-associated membrane protein 7
VC Venus C-terminal part
VN Venus N-terminal part
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